Cluster;ID;Description;GeneRatio;BgRatio;pvalue;p.adjust;qvalue;geneID;Count
NIP;GO:0006457;protein folding;14/183;233/18862;6.70E-08;8.15E-05;7.60E-05;BAG1/BAG2/CCT8L2/CHCHD4/CLGN/DNAJB11/HSPA1A/HSPA2/HSPA5/HSPA8/PPIE/PTGES3/RIC3/RP2;14
NIP;GO:0090150;establishment of protein localization to membrane;17/183;354/18862;6.80E-08;8.15E-05;7.60E-05;CALM1/CHM/GDI1/HSPA5/RPL17/RPS6/SLC1A1/SRP14/SRP68/SRP9/VPS37D/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ/ZDHHC12;17
NIP;GO:0051084;'de novo' posttranslational protein folding;7/183;39/18862;8.54E-08;8.15E-05;7.60E-05;BAG1/CHCHD4/HSPA1A/HSPA2/HSPA5/HSPA8/PTGES3;7
NIP;GO:0006458;'de novo' protein folding;7/183;43/18862;1.73E-07;0.000123924;0.000115644;BAG1/CHCHD4/HSPA1A/HSPA2/HSPA5/HSPA8/PTGES3;7
NIP;GO:0051085;chaperone cofactor-dependent protein refolding;6/183;34/18862;8.24E-07;0.00047227;0.000440713;BAG1/HSPA1A/HSPA2/HSPA5/HSPA8/PTGES3;6
NIP;GO:0021762;substantia nigra development;6/183;43/18862;3.48E-06;0.001443944;0.001347462;CALM1/DYNLL1/HSPA5/INA/YWHAH/YWHAQ;6
NIP;GO:1901028;regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway;6/183;44/18862;3.99E-06;0.001443944;0.001347462;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:1900739;regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway;5/183;26/18862;4.54E-06;0.001443944;0.001347462;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:1900740;positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway;5/183;26/18862;4.54E-06;0.001443944;0.001347462;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:0006605;protein targeting;16/183;441/18862;6.59E-06;0.001826706;0.001704649;CHCHD4/CHM/GDI1/HSPA5/HSPA8/RPL17/RPS6/SLC1A1/SRP14/SRP68/SRP9/VPS37D/YWHAB/YWHAG/YWHAQ/ZDHHC12;16
NIP;GO:0006612;protein targeting to membrane;11/183;211/18862;7.02E-06;0.001826706;0.001704649;CHM/GDI1/HSPA5/RPL17/RPS6/SLC1A1/SRP14/SRP68/SRP9/VPS37D/ZDHHC12;11
NIP;GO:0001844;protein insertion into mitochondrial membrane involved in apoptotic signaling pathway;5/183;30/18862;9.53E-06;0.002273471;0.002121561;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:0090151;establishment of protein localization to mitochondrial membrane;6/183;53/18862;1.21E-05;0.002661378;0.002483549;CALM1/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:0097345;mitochondrial outer membrane permeabilization;6/183;55/18862;1.50E-05;0.003070913;0.002865719;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:0030901;midbrain development;7/183;86/18862;2.03E-05;0.003734622;0.00348508;CALM1/DYNLL1/HSPA5/INA/WNT5A/YWHAH/YWHAQ;7
NIP;GO:1901030;positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway;5/183;35/18862;2.09E-05;0.003734622;0.00348508;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:0048857;neural nucleus development;6/183;60/18862;2.49E-05;0.003962586;0.003697812;CALM1/DYNLL1/HSPA5/INA/YWHAH/YWHAQ;6
NIP;GO:1902110;positive regulation of mitochondrial membrane permeability involved in apoptotic process;6/183;60/18862;2.49E-05;0.003962586;0.003697812;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:1902686;mitochondrial outer membrane permeabilization involved in programmed cell death;6/183;62/18862;3.01E-05;0.0045363;0.00423319;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:0061077;chaperone-mediated protein folding;6/183;63/18862;3.30E-05;0.004725072;0.004409349;BAG1/HSPA1A/HSPA2/HSPA5/HSPA8/PTGES3;6
NIP;GO:0035794;positive regulation of mitochondrial membrane permeability;6/183;64/18862;3.61E-05;0.004925938;0.004596794;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:1902108;regulation of mitochondrial membrane permeability involved in apoptotic process;6/183;66/18862;4.31E-05;0.005607597;0.005232906;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:1905710;positive regulation of membrane permeability;6/183;69/18862;5.55E-05;0.006908789;0.006447154;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:0042026;protein refolding;4/183;23/18862;6.57E-05;0.007842792;0.007318748;HSPA1A/HSPA2/HSPA5/HSPA8;4
NIP;GO:0043312;neutrophil degranulation;15/183;485/18862;8.07E-05;0.009242654;0.008625073;ATP6V1D/C3AR1/CEACAM8/ADA2/DEFA1/DYNLL1/FGL2/FTL/GDI2/HSPA1A/HSPA8/IMPDH1/PPIE/S100P/SRP14;15
NIP;GO:0002283;neutrophil activation involved in immune response;15/183;488/18862;8.64E-05;0.009421787;0.008792236;ATP6V1D/C3AR1/CEACAM8/ADA2/DEFA1/DYNLL1/FGL2/FTL/GDI2/HSPA1A/HSPA8/IMPDH1/PPIE/S100P/SRP14;15
NIP;GO:0046902;regulation of mitochondrial membrane permeability;6/183;75/18862;8.88E-05;0.009421787;0.008792236;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:0051204;protein insertion into mitochondrial membrane;5/183;48/18862;9.94E-05;0.010165179;0.009485956;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:0002446;neutrophil mediated immunity;15/183;499/18862;0.000110573;0.010791315;0.010070255;ATP6V1D/C3AR1/CEACAM8/ADA2/DEFA1/DYNLL1/FGL2/FTL/GDI2/HSPA1A/HSPA8/IMPDH1/PPIE/S100P/SRP14;15
NIP;GO:0042119;neutrophil activation;15/183;500/18862;0.000113038;0.010791315;0.010070255;ATP6V1D/C3AR1/CEACAM8/ADA2/DEFA1/DYNLL1/FGL2/FTL/GDI2/HSPA1A/HSPA8/IMPDH1/PPIE/S100P/SRP14;15
NIP;GO:1905475;regulation of protein localization to membrane;9/183;194/18862;0.000119417;0.011032609;0.010295425;GDI1/PLS1/SLC1A1/TMEM59/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;9
NIP;GO:0051480;regulation of cytosolic calcium ion concentration;12/183;344/18862;0.000140361;0.012562323;0.011722926;APLNR/ATP2B2/C3AR1/CALM1/CCL3/GOT1/GPR17/JPH4/NPTN/PDGFRA/RIC3/WNT5A;12
NIP;GO:0008637;apoptotic mitochondrial changes;7/183;118/18862;0.000153722;0.013341244;0.012449801;ATP2A1/HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
NIP;GO:0090559;regulation of membrane permeability;6/183;90/18862;0.000243603;0.02012356;0.018778932;HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;GO:1903749;positive regulation of establishment of protein localization to mitochondrion;5/183;58/18862;0.000245923;0.02012356;0.018778932;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:0072503;cellular divalent inorganic cation homeostasis;14/183;480/18862;0.000255844;0.020353835;0.01899382;APLNR/ATP2A1/ATP2B2/C3AR1/CALM1/CCL3/GOT1/GPR17/JPH4/NPTN/PDGFRA/RIC3/SLC1A1/WNT5A;14
NIP;GO:0072507;divalent inorganic cation homeostasis;14/183;499/18862;0.000378326;0.029284446;0.027327701;APLNR/ATP2A1/ATP2B2/C3AR1/CALM1/CCL3/GOT1/GPR17/JPH4/NPTN/PDGFRA/RIC3/SLC1A1/WNT5A;14
NIP;GO:0006874;cellular calcium ion homeostasis;13/183;442/18862;0.000392842;0.02960789;0.027629533;APLNR/ATP2A1/ATP2B2/C3AR1/CALM1/CCL3/GOT1/GPR17/JPH4/NPTN/PDGFRA/RIC3/WNT5A;13
NIP;GO:1901021;positive regulation of calcium ion transmembrane transporter activity;4/183;37/18862;0.000440909;0.032378546;0.030215057;ATP2A1/CALM1/HSPA2/KCNE3;4
NIP;GO:0006986;response to unfolded protein;8/183;185/18862;0.000457379;0.032748307;0.030560111;CLGN/DNAJB11/FBXO6/HSPA1A/HSPA2/HSPA5/HSPA8/LMNA;8
NIP;GO:0072655;establishment of protein localization to mitochondrion;7/183;142/18862;0.00047714;0.033329975;0.031102913;CALM1/CHCHD4/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
NIP;GO:0055074;calcium ion homeostasis;13/183;454/18862;0.000505628;0.034479009;0.03217517;APLNR/ATP2A1/ATP2B2/C3AR1/CALM1/CCL3/GOT1/GPR17/JPH4/NPTN/PDGFRA/RIC3/WNT5A;13
NIP;GO:0007006;mitochondrial membrane organization;7/183;144/18862;0.000518869;0.034559072;0.032249884;CALM1/HSPA1A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
NIP;GO:0070585;protein localization to mitochondrion;7/183;146/18862;0.000563454;0.03667576;0.034225138;CALM1/CHCHD4/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
NIP;GO:1904427;positive regulation of calcium ion transmembrane transport;5/183;70/18862;0.000591476;0.037644178;0.035128848;APLNR/ATP2A1/CALM1/HSPA2/KCNE3;5
NIP;GO:0034620;cellular response to unfolded protein;7/183;149/18862;0.000635994;0.039597555;0.036951702;CLGN/DNAJB11/HSPA1A/HSPA2/HSPA5/HSPA8/LMNA;7
NIP;GO:1903747;regulation of establishment of protein localization to mitochondrion;5/183;72/18862;0.00067319;0.041021629;0.038280622;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;GO:0033157;regulation of intracellular protein transport;9/183;248/18862;0.000726849;0.043368679;0.040470845;DMAP1/GDI1/RAN/SLC1A1/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;9
VIP;GO:0010256;endomembrane system organization;27/292;482/18862;9.09E-09;2.93E-05;2.57E-05;AKAP9/ANO6/AP3B1/BAG5/CHMP2A/GCC2/GOLGA2/GOLGB1/GORASP1/HOOK1/LMAN2/NEK9/PDE4DIP/RAB10/RAB18/RAB1A/RAB2A/RAB7A/REEP5/REEP6/RTN4/SLC9A3R1/SUN2/TMED5/TOR1A/TOR1AIP1/VPS11;27
VIP;GO:0006605;protein targeting;25/292;441/18862;2.62E-08;4.22E-05;3.70E-05;AP3B1/CSNK2A2/DNAJC19/GCC2/GOLGA7/GRPEL1/IDE/NUP54/OS9/PITRM1/PMPCA/PMPCB/RAB7A/RPL36/SIL1/SLC27A2/SRP19/SRP54/SRP72/STOM/TIMM10/TIMM8B/TIMM9/TYSND1/VPS11;25
VIP;GO:0034605;cellular response to heat;13/292;120/18862;4.48E-08;4.81E-05;4.22E-05;BAG5/HDAC2/HMOX1/HSBP1/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PRKACA/RAE1/SLU7;13
VIP;GO:0006457;protein folding;17/292;233/18862;1.43E-07;0.000115086;0.000101034;BAG5/CSNK2A2/CSNK2B/CWC27/DNAJC19/ERP44/GNB1/GRPEL1/MOGS/NGLY1/PPIL3/QSOX2/SDF2/SIL1/TBCA/TOR1A/WFS1;17
VIP;GO:0006409;tRNA export from nucleus;7/292;34/18862;7.46E-07;0.000399815;0.000350998;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0071431;tRNA-containing ribonucleoprotein complex export from nucleus;7/292;34/18862;7.46E-07;0.000399815;0.000350998;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0051031;tRNA transport;7/292;37/18862;1.37E-06;0.000514739;0.00045189;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0009408;response to heat;13/292;161/18862;1.39E-06;0.000514739;0.00045189;BAG5/HDAC2/HMOX1/HSBP1/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PRKACA/RAE1/SLU7;13
VIP;GO:0043488;regulation of mRNA stability;14/292;188/18862;1.44E-06;0.000514739;0.00045189;EXOSC2/EXOSC3/EXOSC5/EXOSC8/FASTKD5/GIGYF2/LARP1/LARP4B/MOV10/NUP214/PABPC1/PABPC4/PSMD8/UPF1;14
VIP;GO:0097064;ncRNA export from nucleus;7/292;38/18862;1.66E-06;0.000533719;0.000468553;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0072655;establishment of protein localization to mitochondrion;12/292;142/18862;2.20E-06;0.000642414;0.000563976;AP3B1/BCS1L/CSNK2A2/DNAJC19/GRPEL1/PITRM1/PMPCA/PMPCB/TIMM10/TIMM8B/TIMM9/VPS11;12
VIP;GO:0043487;regulation of RNA stability;14/292;198/18862;2.66E-06;0.000675859;0.000593338;EXOSC2/EXOSC3/EXOSC5/EXOSC8/FASTKD5/GIGYF2/LARP1/LARP4B/MOV10/NUP214/PABPC1/PABPC4/PSMD8/UPF1;14
VIP;GO:0090150;establishment of protein localization to membrane;19/292;354/18862;2.90E-06;0.000675859;0.000593338;ACSL3/AP3B1/ATP1B1/BCS1L/GOLGA7/GORASP1/GRIPAP1/RAB10/RAB7A/RAB8A/RPL36/SIL1/SRP19/SRP54/SRP72/STOM/TIMM10/TIMM8B/TIMM9;19
VIP;GO:0070585;protein localization to mitochondrion;12/292;146/18862;2.94E-06;0.000675859;0.000593338;AP3B1/BCS1L/CSNK2A2/DNAJC19/GRPEL1/PITRM1/PMPCA/PMPCB/TIMM10/TIMM8B/TIMM9/VPS11;12
VIP;GO:0006626;protein targeting to mitochondrion;10/292;100/18862;3.44E-06;0.000723788;0.000635415;CSNK2A2/DNAJC19/GRPEL1/PITRM1/PMPCA/PMPCB/TIMM10/TIMM8B/TIMM9/VPS11;10
VIP;GO:1900034;regulation of cellular response to heat;9/292;79/18862;3.60E-06;0.000723788;0.000635415;BAG5/HSBP1/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;9
VIP;GO:0007030;Golgi organization;12/292;150/18862;3.90E-06;0.000738047;0.000647933;AKAP9/BAG5/GCC2/GOLGA2/GOLGB1/GORASP1/HOOK1/LMAN2/PDE4DIP/RAB1A/RAB2A/TMED5;12
VIP;GO:0061013;regulation of mRNA catabolic process;14/292;210/18862;5.28E-06;0.00094328;0.000828107;EXOSC2/EXOSC3/EXOSC5/EXOSC8/FASTKD5/GIGYF2/LARP1/LARP4B/MOV10/NUP214/PABPC1/PABPC4/PSMD8/UPF1;14
VIP;GO:0016073;snRNA metabolic process;7/292;47/18862;7.34E-06;0.001210968;0.001063111;EXOSC2/EXOSC3/EXOSC5/EXOSC8/INTS4/LARP7/MEPCE;7
VIP;GO:0044766;multi-organism transport;8/292;66/18862;7.90E-06;0.001210968;0.001063111;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAB7A/RAE1;8
VIP;GO:1902579;multi-organism localization;8/292;66/18862;7.90E-06;0.001210968;0.001063111;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAB7A/RAE1;8
VIP;GO:0019058;viral life cycle;18/292;348/18862;8.83E-06;0.001248833;0.001096352;CHMP2A/IDE/ITGB1/LARP1/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PABPC1/PVR/RAB1A/RAB7A/RAE1/SCARB1/STOM/TMEM39B;18
VIP;GO:0007249;I-kappaB kinase/NF-kappaB signaling;16/292;282/18862;8.93E-06;0.001248833;0.001096352;BRD4/DDX21/ERC1/F2RL1/HMOX1/NDFIP2/NLRX1/NUP62/RHOA/RIPK1/SLC44A2/SNIP1/TBK1/TBKBP1/TLE1/TRIM59;16
VIP;GO:0009100;glycoprotein metabolic process;20/292;421/18862;9.88E-06;0.001324171;0.001162493;AATF/ALG11/ALG5/ALG8/CHPF/CHPF2/DPY19L1/EDEM3/ERP44/GOLGA2/GORASP1/HS2ST1/HS6ST2/MOGS/NGLY1/OS9/PCSK6/POFUT1/RAB1A/UGGT2;20
VIP;GO:0034427;nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5';4/292;11/18862;1.70E-05;0.002108788;0.001851309;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:0072321;chaperone-mediated protein transport;4/292;11/18862;1.70E-05;0.002108788;0.001851309;TIMM10/TIMM8B/TIMM9/TOR1A;4
VIP;GO:0031126;sno(s)RNA 3'-end processing;4/292;12/18862;2.53E-05;0.002805693;0.002463123;EXOSC2/EXOSC3/EXOSC5/LARP7;4
VIP;GO:0051028;mRNA transport;11/292;152/18862;2.54E-05;0.002805693;0.002463123;G3BP2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/RAE1/SLU7/UPF1;11
VIP;GO:0022406;membrane docking;12/292;181/18862;2.63E-05;0.002805693;0.002463123;AKAP9/CDK5RAP2/CEP135/CEP250/NINL/PCNT/PRKACA/PRKAR2B/RAB10/RAB7A/RAB8A/VPS11;12
VIP;GO:0072659;protein localization to plasma membrane;15/292;275/18862;2.70E-05;0.002805693;0.002463123;ACSL3/AP2M1/ARF6/ATP1B1/GOLGA7/GORASP1/GRIPAP1/ITGB1/PKP2/RAB10/RAB7A/RAB8A/RDX/SLC9A3R1/ZDHHC5;15
VIP;GO:0075733;intracellular transport of virus;7/292;57/18862;2.70E-05;0.002805693;0.002463123;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0036503;ERAD pathway;9/292;102/18862;2.94E-05;0.002953309;0.002592716;EDEM3/ERLEC1/FOXRED2/OS9/TOR1A/UBXN8/UGGT2/USP13/WFS1;9
VIP;GO:0061951;establishment of protein localization to plasma membrane;7/292;59/18862;3.40E-05;0.003221763;0.002828392;ACSL3/GOLGA7/GORASP1/GRIPAP1/RAB10/RAB7A/RAB8A;7
VIP;GO:0071027;nuclear RNA surveillance;4/292;13/18862;3.60E-05;0.003221763;0.002828392;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:0071028;nuclear mRNA surveillance;4/292;13/18862;3.60E-05;0.003221763;0.002828392;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:0002446;neutrophil mediated immunity;21/292;499/18862;3.61E-05;0.003221763;0.002828392;ANO6/AP2A2/CSNK2B/CYB5R3/ERP44/F2RL1/GGH/GLA/GOLGA7/IMPDH2/NPC2/PTGES2/RAB10/RAB14/RAB18/RAB5C/RAB7A/RHOA/SLC27A2/SLC44A2/STOM;21
VIP;GO:0042119;neutrophil activation;21/292;500/18862;3.71E-05;0.003226972;0.002832965;ANO6/AP2A2/CSNK2B/CYB5R3/ERP44/F2RL1/GGH/GLA/GOLGA7/IMPDH2/NPC2/PTGES2/RAB10/RAB14/RAB18/RAB5C/RAB7A/RHOA/SLC27A2/SLC44A2/STOM;21
VIP;GO:0010457;centriole-centriole cohesion;4/292;14/18862;4.98E-05;0.004110617;0.003608719;CEP135/CEP250/CEP68/NIN;4
VIP;GO:0043144;sno(s)RNA processing;4/292;14/18862;4.98E-05;0.004110617;0.003608719;EXOSC2/EXOSC3/EXOSC5/LARP7;4
VIP;GO:0032201;telomere maintenance via semi-conservative replication;5/292;27/18862;5.25E-05;0.004218412;0.003703352;POLA1/POLA2/PRIM1/PRIM2/UPF1;5
VIP;GO:0046794;transport of virus;7/292;64/18862;5.79E-05;0.00441738;0.003878026;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:1990778;protein localization to cell periphery;16/292;329/18862;5.85E-05;0.00441738;0.003878026;ACSL3/AP2M1/ARF6/ATP1B1/GOLGA7/GORASP1/GRIPAP1/ITGB1/PDZD11/PKP2/RAB10/RAB7A/RAB8A/RDX/SLC9A3R1/ZDHHC5;16
VIP;GO:0009266;response to temperature stimulus;13/292;228/18862;5.90E-05;0.00441738;0.003878026;BAG5/HDAC2/HMOX1/HSBP1/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PRKACA/RAE1/SLU7;13
VIP;GO:0006406;mRNA export from nucleus;9/292;113/18862;6.60E-05;0.004681781;0.004110145;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/SLU7/UPF1;9
VIP;GO:0071427;mRNA-containing ribonucleoprotein complex export from nucleus;9/292;113/18862;6.60E-05;0.004681781;0.004110145;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/SLU7/UPF1;9
VIP;GO:0071025;RNA surveillance;4/292;15/18862;6.71E-05;0.004681781;0.004110145;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:0010498;proteasomal protein catabolic process;20/292;483/18862;6.92E-05;0.004681781;0.004110145;ATE1/BAG5/CUL2/EDEM3/ERLEC1/FBXL12/FOXRED2/GPX1/HECTD1/OS9/PRKACA/PSMD8/RBX1/RNF41/TOR1A/UBXN8/UGGT2/USP13/WFS1/ZYG11B;20
VIP;GO:1903311;regulation of mRNA metabolic process;16/292;334/18862;6.99E-05;0.004681781;0.004110145;EXOSC2/EXOSC3/EXOSC5/EXOSC8/FASTKD5/GIGYF2/LARP1/LARP4B/LARP7/MOV10/NUP214/NUP98/PABPC1/PABPC4/PSMD8/UPF1;16
VIP;GO:0043312;neutrophil degranulation;20/292;485/18862;7.32E-05;0.004786039;0.004201673;ANO6/AP2A2/CSNK2B/CYB5R3/ERP44/GGH/GLA/GOLGA7/IMPDH2/NPC2/PTGES2/RAB10/RAB14/RAB18/RAB5C/RAB7A/RHOA/SLC27A2/SLC44A2/STOM;20
VIP;GO:0048193;Golgi vesicle transport;17/292;372/18862;7.44E-05;0.004786039;0.004201673;ACSL3/ERGIC1/GCC2/GOLGA2/GOLGA3/GOLGA7/GOLGB1/GORASP1/HYOU1/LMAN2/RAB10/RAB14/RAB1A/RAB8A/SCAP/TMED5/YIF1A;17
VIP;GO:0006403;RNA localization;13/292;234/18862;7.69E-05;0.004786039;0.004201673;EXOSC2/EXOSC3/G3BP2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/RAE1/SLU7/UPF1;13
VIP;GO:0140056;organelle localization by membrane tethering;11/292;172/18862;7.88E-05;0.004786039;0.004201673;AKAP9/CDK5RAP2/CEP135/CEP250/NINL/PCNT/PRKACA/PRKAR2B/RAB10/RAB8A/VPS11;11
VIP;GO:0002283;neutrophil activation involved in immune response;20/292;488/18862;7.96E-05;0.004786039;0.004201673;ANO6/AP2A2/CSNK2B/CYB5R3/ERP44/GGH/GLA/GOLGA7/IMPDH2/NPC2/PTGES2/RAB10/RAB14/RAB18/RAB5C/RAB7A/RHOA/SLC27A2/SLC44A2/STOM;20
VIP;GO:0010389;regulation of G2/M transition of mitotic cell cycle;12/292;203/18862;8.03E-05;0.004786039;0.004201673;AKAP9/BRD4/CDK5RAP2/CENPF/CEP135/CEP250/NINL/PCNT/PRKACA/PRKAR2B/PSMD8/RBX1;12
VIP;GO:0016074;sno(s)RNA metabolic process;4/292;16/18862;8.84E-05;0.005120555;0.004495345;EXOSC2/EXOSC3/EXOSC5/LARP7;4
VIP;GO:0007020;microtubule nucleation;5/292;30/18862;8.91E-05;0.005120555;0.004495345;AKAP9/GOLGA2/NIN/TUBGCP2/TUBGCP3;5
VIP;GO:0042254;ribosome biogenesis;15/292;307/18862;9.43E-05;0.005323193;0.004673241;AATF/DDX10/DDX21/EXOSC2/EXOSC3/EXOSC5/EXOSC8/HEATR3/MDN1/MPHOSPH10/MRPS2/NGDN/NOL10/NUP88/RRP9;15
VIP;GO:0044839;cell cycle G2/M phase transition;14/292;276/18862;0.00010866;0.006026889;0.005291017;AKAP8/AKAP9/BRD4/CDK5RAP2/CENPF/CEP135/CEP250/FBXL12/NINL/PCNT/PRKACA/PRKAR2B/PSMD8/RBX1;14
VIP;GO:0060964;regulation of gene silencing by miRNA;9/292;121/18862;0.000112215;0.006091109;0.005347396;EIF4E2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/RIPK1;9
VIP;GO:0097711;ciliary basal body-plasma membrane docking;8/292;95/18862;0.000113605;0.006091109;0.005347396;AKAP9/CDK5RAP2/CEP135/CEP250/NINL/PCNT/PRKACA/PRKAR2B;8
VIP;GO:0043122;regulation of I-kappaB kinase/NF-kappaB signaling;13/292;244/18862;0.000117185;0.006180087;0.005425511;BRD4/DDX21/F2RL1/HMOX1/NDFIP2/NLRX1/NUP62/RHOA/RIPK1/SLC44A2/TBK1/TLE1/TRIM59;13
VIP;GO:0032386;regulation of intracellular transport;16/292;350/18862;0.000120422;0.006248365;0.005485451;CSNK2A2/ERLEC1/GCC2/GRIPAP1/NUP214/NUP54/NUP62/NUTF2/OS9/PCNT/PRKACA/RDX/REEP5/REEP6/STOM/VPS11;16
VIP;GO:0060147;regulation of posttranscriptional gene silencing;9/292;124/18862;0.000135381;0.006883311;0.006042872;EIF4E2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/RIPK1;9
VIP;GO:0006611;protein export from nucleus;11/292;183/18862;0.000136939;0.006883311;0.006042872;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/PRKACA/RAE1/SLU7/UPF1;11
VIP;GO:0060966;regulation of gene silencing by RNA;9/292;125/18862;0.000143938;0.007123848;0.00625404;EIF4E2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/RIPK1;9
VIP;GO:1902749;regulation of cell cycle G2/M phase transition;12/292;219/18862;0.000164461;0.008016236;0.00703747;AKAP9/BRD4/CDK5RAP2/CENPF/CEP135/CEP250/NINL/PCNT/PRKACA/PRKAR2B/PSMD8/RBX1;12
VIP;GO:0071426;ribonucleoprotein complex export from nucleus;9/292;130/18862;0.000193805;0.009305515;0.00816933;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/SLU7/UPF1;9
VIP;GO:0000086;G2/M transition of mitotic cell cycle;13/292;258/18862;0.000203387;0.009573048;0.008404197;AKAP9/BRD4/CDK5RAP2/CENPF/CEP135/CEP250/FBXL12/NINL/PCNT/PRKACA/PRKAR2B/PSMD8/RBX1;13
VIP;GO:0071166;ribonucleoprotein complex localization;9/292;131/18862;0.000205328;0.009573048;0.008404197;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/SLU7/UPF1;9
VIP;GO:1903829;positive regulation of cellular protein localization;14/292;295/18862;0.000217244;0.009744524;0.008554736;ACSL3/ARF6/CEP250/CSNK2A2/ITGB1/LARP7/MEPCE/NUP62/NUTF2/RDX/RTN4/STOM/VPS11/ZDHHC5;14
VIP;GO:0016180;snRNA processing;5/292;36/18862;0.000218575;0.009744524;0.008554736;EXOSC2/EXOSC3/EXOSC5/EXOSC8/INTS4;5
VIP;GO:0006110;regulation of glycolytic process;7/292;79/18862;0.000221886;0.009744524;0.008554736;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0016075;rRNA catabolic process;4/292;20/18862;0.000224151;0.009744524;0.008554736;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:0046931;pore complex assembly;4/292;20/18862;0.000224151;0.009744524;0.008554736;ANO6/NUP98/PDZD11/RTN4;4
VIP;GO:0009896;positive regulation of catabolic process;18/292;450/18862;0.000243307;0.010436237;0.009161993;ADAM9/FYCO1/GIGYF2/HECTD1/HMOX1/IDE/LARP1/MOV10/PABPC1/RAB7A/RBX1/RDX/RNF41/TBK1/UPF1/USP13/VPS11/ZYG11B;18
VIP;GO:0016925;protein sumoylation;7/292;81/18862;0.000259264;0.010939179;0.009603526;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0006402;mRNA catabolic process;16/292;375/18862;0.000263303;0.010939179;0.009603526;CSDE1/EXOSC2/EXOSC3/EXOSC5/EXOSC8/FASTKD5/GIGYF2/LARP1/LARP4B/MOV10/NUP214/PABPC1/PABPC4/PSMD8/RPL36/UPF1;16
VIP;GO:0019080;viral gene expression;11/292;198/18862;0.000272034;0.010939179;0.009603526;CSDE1/GTF2F2/LARP7/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/RPL36;11
VIP;GO:0050657;nucleic acid transport;11/292;198/18862;0.000272034;0.010939179;0.009603526;G3BP2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/RAE1/SLU7/UPF1;11
VIP;GO:0050658;RNA transport;11/292;198/18862;0.000272034;0.010939179;0.009603526;G3BP2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/RAE1/SLU7/UPF1;11
VIP;GO:0051168;nuclear export;11/292;201/18862;0.000309485;0.012141621;0.010659153;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/PRKACA/RAE1/SLU7/UPF1;11
VIP;GO:0051236;establishment of RNA localization;11/292;201/18862;0.000309485;0.012141621;0.010659153;G3BP2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/RAE1/SLU7/UPF1;11
VIP;GO:0031023;microtubule organizing center organization;9/292;140/18862;0.0003371;0.013065664;0.011470372;CDK5RAP2/CEP135/CEP250/CEP68/CHMP2A/GCC2/GOLGA2/NIN/NUP62;9
VIP;GO:0009101;glycoprotein biosynthetic process;15/292;347/18862;0.000355469;0.013613605;0.01195141;AATF/ALG11/ALG5/ALG8/CHPF/CHPF2/DPY19L1/EDEM3/GOLGA2/GORASP1/HS2ST1/HS6ST2/MOGS/POFUT1/UGGT2;15
VIP;GO:0006839;mitochondrial transport;13/292;274/18862;0.000363747;0.013766767;0.012085871;BCS1L/CSNK2A2/DNAJC19/GRPEL1/PITRM1/PMPCA/PMPCB/SLC25A21/STOML2/TIMM10/TIMM8B/TIMM9/VPS11;13
VIP;GO:0006405;RNA export from nucleus;9/292;142/18862;0.000374285;0.01400088;0.0122914;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/SLU7/UPF1;9
VIP;GO:1902850;microtubule cytoskeleton organization involved in mitosis;9/292;143/18862;0.000394109;0.014572974;0.012793642;CDK5RAP2/CHMP2A/GOLGA2/ITGB1/NUP62/PCNT/RAE1/RHOA/SUN2;9
VIP;GO:0031125;rRNA 3'-end processing;3/292;10/18862;0.000406534;0.01474473;0.012944427;EXOSC2/EXOSC3/EXOSC8;3
VIP;GO:0034383;low-density lipoprotein particle clearance;5/292;41/18862;0.000407921;0.01474473;0.012944427;AP2A2/AP2M1/HMOX1/NPC2/SCARB1;5
VIP;GO:0060968;regulation of gene silencing;9/292;144/18862;0.00041479;0.01482644;0.013016161;EIF4E2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/RIPK1;9
VIP;GO:0051656;establishment of organelle localization;17/292;431/18862;0.00042327;0.014963287;0.013136298;AP3B1/ATP6AP1/CDK5RAP2/CENPF/CHMP2A/FYCO1/GOLGA2/GORASP1/HMOX1/ITGB1/MARK1/NUP62/NUP88/RAB1A/SLC9A3R1/SUN2/TOR1A;17
VIP;GO:0043470;regulation of carbohydrate catabolic process;7/292;90/18862;0.000495038;0.017004412;0.014928206;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0010257;NADH dehydrogenase complex assembly;6/292;65/18862;0.000502001;0.017004412;0.014928206;ACAD9/BCS1L/ECSIT/NDUFAF1/NDUFAF2/NDUFB9;6
VIP;GO:0032981;mitochondrial respiratory chain complex I assembly;6/292;65/18862;0.000502001;0.017004412;0.014928206;ACAD9/BCS1L/ECSIT/NDUFAF1/NDUFAF2/NDUFB9;6
VIP;GO:0033157;regulation of intracellular protein transport;12/292;248/18862;0.000510749;0.017004412;0.014928206;CSNK2A2/ERLEC1/GCC2/GRIPAP1/NUP54/NUP62/NUTF2/OS9/PCNT/PRKACA/STOM/VPS11;12
VIP;GO:0000413;protein peptidyl-prolyl isomerization;5/292;43/18862;0.000510928;0.017004412;0.014928206;CWC27/FKBP10/FKBP15/FKBP7/PPIL3;5
VIP;GO:0019083;viral transcription;10/292;180/18862;0.000512722;0.017004412;0.014928206;GTF2F2/LARP7/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/RPL36;10
VIP;GO:0045039;protein insertion into mitochondrial inner membrane;3/292;11/18862;0.000552593;0.018139703;0.015924881;TIMM10/TIMM8B/TIMM9;3
VIP;GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;10/292;182/18862;0.000558984;0.01816416;0.015946351;BRD4/DDX21/F2RL1/HMOX1/NDFIP2/NUP62/RHOA/RIPK1/SLC44A2/TBK1;10
VIP;GO:0045185;maintenance of protein location;7/292;92/18862;0.000565444;0.018190318;0.015969315;FBN1/FBN2/G3BP2/GPAA1/OS9/SUN2/TAPT1;7
VIP;GO:0098876;vesicle-mediated transport to the plasma membrane;7/292;93/18862;0.000603511;0.019196027;0.016852229;ACSL3/GOLGA7/GRIPAP1/RAB10/RAB7A/RAB8A/VPS39;7
VIP;GO:0015931;nucleobase-containing compound transport;12/292;253/18862;0.000609558;0.019196027;0.016852229;G3BP2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/RAE1/RIPK1/SLU7/UPF1;12
VIP;GO:0070972;protein localization to endoplasmic reticulum;9/292;152/18862;0.000614607;0.019196027;0.016852229;GPAA1/OS9/RAB10/RPL36/RTN4/SRP19/SRP54/SRP72/TAPT1;9
VIP;GO:1902115;regulation of organelle assembly;10/292;187/18862;0.000689949;0.021244608;0.018650683;CDK5RAP2/CEP135/CHMP2A/G3BP1/G3BP2/NUP62/RDX/TAPT1/TMEM39B/VPS11;10
VIP;GO:0034660;ncRNA metabolic process;18/292;492/18862;0.000698685;0.021244608;0.018650683;DDX10/DDX21/EXOSC2/EXOSC3/EXOSC5/EXOSC8/INTS4/LARP7/MDN1/MEPCE/MPHOSPH10/NARS2/NGDN/NOL10/PUSL1/RRP9/SEPSECS/TRMT1;18
VIP;GO:0006997;nucleus organization;8/292;124/18862;0.000700009;0.021244608;0.018650683;CHMP2A/NEK9/NUP54/NUP98/RTN4/SUN2/TOR1A/TOR1AIP1;8
VIP;GO:0034453;microtubule anchoring;4/292;27/18862;0.00074559;0.022370895;0.019639452;CEP350/GCC2/NIN/NINL;4
VIP;GO:0034976;response to endoplasmic reticulum stress;13/292;296/18862;0.000751028;0.022370895;0.019639452;EDEM3/ERLEC1/ERMP1/ERP44/FOXRED2/HYOU1/OS9/TOR1A/UBXN8/UGGT2/USP13/WFS1/YIF1A;13
VIP;GO:0006401;RNA catabolic process;16/292;414/18862;0.000772495;0.022799221;0.02001548;CSDE1/EXOSC2/EXOSC3/EXOSC5/EXOSC8/FASTKD5/GIGYF2/LARP1/LARP4B/MOV10/NUP214/PABPC1/PABPC4/PSMD8/RPL36/UPF1;16
VIP;GO:0006515;protein quality control for misfolded or incompletely synthesized proteins;4/292;28/18862;0.000859346;0.025131973;0.022063408;NGLY1/TOR1A/UGGT2/ZYG11B;4
VIP;GO:0043467;regulation of generation of precursor metabolites and energy;9/292;160/18862;0.000887102;0.025502192;0.022388424;GHITM/IDE/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;9
VIP;GO:0006364;rRNA processing;11/292;228/18862;0.00088786;0.025502192;0.022388424;DDX10/DDX21/EXOSC2/EXOSC3/EXOSC5/EXOSC8/MDN1/MPHOSPH10/NGDN/NOL10/RRP9;11
VIP;GO:0007098;centrosome cycle;8/292;129/18862;0.00090709;0.025823969;0.022670913;CDK5RAP2/CEP135/CEP250/CEP68/CHMP2A/GOLGA2/NIN/NUP62;8
VIP;GO:0034982;mitochondrial protein processing;3/292;13/18862;0.000936074;0.025959917;0.022790261;PMPCA/PMPCB/STOML2;3
VIP;GO:0090161;Golgi ribbon formation;3/292;13/18862;0.000936074;0.025959917;0.022790261;GCC2/GOLGA2/TMED5;3
VIP;GO:1904668;positive regulation of ubiquitin protein ligase activity;3/292;13/18862;0.000936074;0.025959917;0.022790261;GOLGA2/GORASP1/RAB1A;3
VIP;GO:0042176;regulation of protein catabolic process;15/292;383/18862;0.000980744;0.026676672;0.023419502;ADAM9/BAG5/CSNK2A2/GPX1/HECTD1/IDE/MYCBP2/PRKACA/RAB7A/RBX1/RDX/RNF41/USP13/VPS11/ZYG11B;15
VIP;GO:0006517;protein deglycosylation;4/292;29/18862;0.000984805;0.026676672;0.023419502;EDEM3/NGLY1/OS9/UGGT2;4
VIP;GO:0097006;regulation of plasma lipoprotein particle levels;7/292;101/18862;0.000986796;0.026676672;0.023419502;ACSL3/AP2A2/AP2M1/HMOX1/NPC2/PRKACA/SCARB1;7
VIP;GO:0006487;protein N-linked glycosylation;6/292;74/18862;0.001002672;0.026764595;0.02349669;ALG11/ALG5/ALG8/GORASP1/MOGS/UGGT2;6
VIP;GO:0031331;positive regulation of cellular catabolic process;15/292;384/18862;0.001006688;0.026764595;0.02349669;ADAM9/FYCO1/GIGYF2/HECTD1/HMOX1/LARP1/MOV10/PABPC1/RBX1/RDX/TBK1/UPF1/USP13/VPS11/ZYG11B;15
VIP;GO:0043628;ncRNA 3'-end processing;5/292;50/18862;0.001029773;0.027153924;0.023838482;EXOSC2/EXOSC3/EXOSC5/EXOSC8/LARP7;5
VIP;GO:0006999;nuclear pore organization;3/292;14/18862;0.001177776;0.030098976;0.026423949;NUP54/NUP98/RTN4;3
VIP;GO:0035437;maintenance of protein localization in endoplasmic reticulum;3/292;14/18862;0.001177776;0.030098976;0.026423949;GPAA1/OS9/TAPT1;3
VIP;GO:0099638;endosome to plasma membrane protein transport;3/292;14/18862;0.001177776;0.030098976;0.026423949;GRIPAP1/RAB7A/RAB8A;3
VIP;GO:0016236;macroautophagy;13/292;311/18862;0.001178884;0.030098976;0.026423949;ATP6V1A/CHMP2A/CSNK2A2/CSNK2B/FYCO1/HMOX1/LARP1/PRKACA/RAB1A/RAB7A/RNF41/TBK1/TMEM39B;13
VIP;GO:0006998;nuclear envelope organization;5/292;52/18862;0.001231821;0.030800117;0.027039482;CHMP2A/NEK9/SUN2/TOR1A/TOR1AIP1;5
VIP;GO:0046785;microtubule polymerization;6/292;77/18862;0.001234726;0.030800117;0.027039482;AKAP9/CDK5RAP2/GOLGA2/NIN/TUBGCP2/TUBGCP3;6
VIP;GO:0046034;ATP metabolic process;13/292;313/18862;0.001248892;0.030800117;0.027039482;ATP1B1/ATP6V1A/GHITM/NDUFAF1/NDUFB9/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1/STOML2;13
VIP;GO:0034504;protein localization to nucleus;12/292;275/18862;0.001255807;0.030800117;0.027039482;HEATR3/LARP7/MEPCE/NUP214/NUP54/NUP62/NUP88/NUP98/NUTF2/SUN2/TOR1A/TOR1AIP1;12
VIP;GO:0016072;rRNA metabolic process;11/292;238/18862;0.001256553;0.030800117;0.027039482;DDX10/DDX21/EXOSC2/EXOSC3/EXOSC5/EXOSC8/MDN1/MPHOSPH10/NGDN/NOL10/RRP9;11
VIP;GO:0034472;snRNA 3'-end processing;4/292;31/18862;0.001273365;0.030800117;0.027039482;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:1990126;retrograde transport, endosome to plasma membrane;4/292;31/18862;0.001273365;0.030800117;0.027039482;GRIPAP1/RAB7A/RAB8A/VPS39;4
VIP;GO:0030010;establishment of cell polarity;8/292;137/18862;0.001338024;0.032007129;0.028099121;ARF6/CDK5RAP2/ITGB1/MARK2/RAB10/RHOA/RNF41/SLC9A3R1;8
VIP;GO:0090151;establishment of protein localization to mitochondrial membrane;5/292;53/18862;0.001343165;0.032007129;0.028099121;AP3B1/BCS1L/TIMM10/TIMM8B/TIMM9;5
VIP;GO:0016197;endosomal transport;11/292;242/18862;0.001435568;0.033787176;0.029661827;AP3B1/ARF6/CHMP2A/ERC1/GCC2/GRIPAP1/RAB10/RAB14/RAB7A/RAB8A/VPS39;11
VIP;GO:0006888;endoplasmic reticulum to Golgi vesicle-mediated transport;10/292;206/18862;0.001438869;0.033787176;0.029661827;ERGIC1/GOLGA2/GOLGB1/GORASP1/HYOU1/LMAN2/RAB1A/SCAP/TMED5/YIF1A;10
VIP;GO:0006163;purine nucleotide metabolic process;16/292;441/18862;0.001490697;0.03475053;0.030507558;AASS/ACSL3/ATP6V1A/DCAKD/FAR2/GPX1/IMPDH2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PPT1/RAE1/STOML2;16
VIP;GO:0034470;ncRNA processing;15/292;400/18862;0.001507632;0.034892461;0.030632159;DDX10/DDX21/EXOSC2/EXOSC3/EXOSC5/EXOSC8/INTS4/LARP7/MDN1/MPHOSPH10/NGDN/NOL10/PUSL1/RRP9/TRMT1;15
VIP;GO:0006900;vesicle budding from membrane;7/292;109/18862;0.001539928;0.035385336;0.031064855;AP2M1/AP3B1/GOLGA2/GORASP1/RAB1A/RAB7A/SCAP;7
VIP;GO:0043928;exonucleolytic catabolism of deadenylated mRNA;4/292;33/18862;0.001616324;0.03661771;0.032146759;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:0071539;protein localization to centrosome;4/292;33/18862;0.001616324;0.03661771;0.032146759;CEP250/CEP350/GOLGB1/NUP62;4
VIP;GO:0007007;inner mitochondrial membrane organization;5/292;56/18862;0.001721837;0.038735304;0.034005799;DNAJC11/GHITM/TIMM10/TIMM8B/TIMM9;5
VIP;GO:0009150;purine ribonucleotide metabolic process;15/292;408/18862;0.00182777;0.040832888;0.035847271;AASS/ACSL3/ATP6V1A/DCAKD/FAR2/IMPDH2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PPT1/RAE1/STOML2;15
VIP;GO:0006096;glycolytic process;7/292;114/18862;0.001992276;0.04417788;0.038783847;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0000291;nuclear-transcribed mRNA catabolic process, exonucleolytic;4/292;35/18862;0.002018697;0.04417788;0.038783847;EXOSC2/EXOSC3/EXOSC5/EXOSC8;4
VIP;GO:1905508;protein localization to microtubule organizing center;4/292;35/18862;0.002018697;0.04417788;0.038783847;CEP250/CEP350/GOLGB1/NUP62;4
VIP;GO:0006757;ATP generation from ADP;7/292;115/18862;0.002093939;0.045514877;0.039957599;NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/RAE1;7
VIP;GO:0007051;spindle organization;9/292;182/18862;0.002169272;0.046168147;0.040531106;CHMP2A/GOLGA2/NUP62/PCNT/RAE1/RHOA/SUN2/TUBGCP2/TUBGCP3;9
VIP;GO:0018208;peptidyl-proline modification;5/292;59/18862;0.002173437;0.046168147;0.040531106;CWC27/FKBP10/FKBP15/FKBP7/PPIL3;5
VIP;GO:0033260;nuclear DNA replication;5/292;59/18862;0.002173437;0.046168147;0.040531106;POLA1/POLA2/PRIM1/PRIM2/UPF1;5
VIP;GO:0007029;endoplasmic reticulum organization;6/292;86/18862;0.002181398;0.046168147;0.040531106;LMAN2/RAB10/RAB18/REEP5/REEP6/RTN4;6
VIP;GO:1903725;regulation of phospholipid metabolic process;4/292;36/18862;0.002243712;0.047176617;0.041416443;ACSL3/DNAJC19/SCARB1/STOML2;4
VIP;GO:0072521;purine-containing compound metabolic process;16/292;460/18862;0.002280541;0.047639616;0.041822911;AASS/ACSL3/ATP6V1A/DCAKD/FAR2/GPX1/IMPDH2/NUP210/NUP214/NUP54/NUP62/NUP88/NUP98/PPT1/RAE1/STOML2;16
VIP;GO:0007052;mitotic spindle organization;7/292;118/18862;0.002423131;0.049969318;0.043868161;CHMP2A/GOLGA2/NUP62/PCNT/RAE1/RHOA/SUN2;7
VIP;GO:0031398;positive regulation of protein ubiquitination;7/292;118/18862;0.002423131;0.049969318;0.043868161;GOLGA2/GORASP1/MYCBP2/NDFIP2/RAB1A/RBX1/WFS1;7
NIP;hsa04114;Oocyte meiosis;Sept-86;131/8101;9.22E-06;0.001155639;0.001084101;CALM1/MAD2L1/PRKACB/SKP1/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;9
NIP;hsa04141;Protein processing in endoplasmic reticulum;Oct-86;171/8101;1.20E-05;0.001155639;0.001084101;BAG1/BAG2/DNAJB11/FBXO2/FBXO6/HSPA1A/HSPA2/HSPA5/HSPA8/SKP1;10
NIP;hsa03060;Protein export;Apr-86;23/8101;8.99E-05;0.005782139;0.005424204;HSPA5/SRP14/SRP68/SRP9;4
NIP;hsa04110;Cell cycle;Jul-86;126/8101;0.000361617;0.017448037;0.016367943;MAD2L1/SKP1/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
NIP;hsa04915;Estrogen signaling pathway;Jun-86;138/8101;0.003375599;0.126939109;0.119081139;CALM1/HSPA1A/HSPA2/HSPA8/KRT38/PRKACB;6
NIP;hsa04213;Longevity regulating pathway - multiple species;Apr-86;62/8101;0.004135478;0.126939109;0.119081139;HSPA1A/HSPA2/HSPA8/PRKACB;4
NIP;hsa03040;Spliceosome;Jun-86;147/8101;0.004604009;0.126939109;0.119081139;HSPA1A/HSPA2/HSPA8/PPIE/SRSF3/SRSF6;6
NIP;hsa05203;Viral carcinogenesis;Jul-86;204/8101;0.005798373;0.135652032;0.127254701;HPN/PRKACB/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
NIP;hsa04390;Hippo signaling pathway;Jun-86;157/8101;0.006325742;0.135652032;0.127254701;WNT5A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
NIP;hsa04612;Antigen processing and presentation;Apr-86;78/8101;0.00930491;0.179584757;0.168467839;HSPA1A/HSPA2/HSPA5/HSPA8;4
NIP;hsa04962;Vasopressin-regulated water reabsorption;Mar-86;44/8101;0.011182747;0.196206387;0.184060532;DYNLL1/DYNLL2/PRKACB;3
NIP;hsa04020;Calcium signaling pathway;Jul-86;240/8101;0.013546735;0.21787666;0.20438934;ATP2A1/ATP2B2/CALM1/PDGFRA/PLCD3/PRKACB/TACR3;7
NIP;hsa05150;Staphylococcus aureus infection;Apr-86;96/8101;0.018779611;0.278805;0.261546005;C1QA/C3AR1/DEFA1/KRT38;4
NIP;hsa05134;Legionellosis;Mar-86;57/8101;0.02239489;0.299726554;0.281172442;HSPA1A/HSPA2/HSPA8;3
NIP;hsa05160;Hepatitis C;May-86;157/8101;0.02543475;0.299726554;0.281172442;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
NIP;hsa05020;Prion disease;Jul-86;273/8101;0.025542416;0.299726554;0.281172442;C1QA/HSPA1A/HSPA2/HSPA5/HSPA8/PRKACB/TUBB8;7
NIP;hsa05417;Lipid and atherosclerosis;Jun-86;215/8101;0.026400785;0.299726554;0.281172442;CALM1/CCL3/HSPA1A/HSPA2/HSPA5/HSPA8;6
NIP;hsa04151;PI3K-Akt signaling pathway;Aug-86;354/8101;0.033708304;0.361427922;0.339054282;EFNA4/PDGFRA/RPS6/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;8
NIP;hsa04010;MAPK signaling pathway;Jul-86;294/8101;0.036164775;0.367357974;0.344617243;DUSP16/EFNA4/HSPA1A/HSPA2/HSPA8/PDGFRA/PRKACB;7
NIP;hsa04919;Thyroid hormone signaling pathway;Apr-86;121/8101;0.039420721;0.380409955;0.356861262;ATP2A1/NOTCH2/PLCD3/PRKACB;4
NIP;hsa05132;Salmonella infection;Jun-86;249/8101;0.048541654;0.446120919;0.418504489;BRK1/DYNLL1/DYNLL2/RILP/SKP1/TUBB8;6
NIP;hsa04144;Endocytosis;Jun-86;252/8101;0.05091964;0.446704116;0.419051584;AMPH/HSPA1A/HSPA2/HSPA8/PDGFRA/VPS37D;6
NIP;hsa04910;Insulin signaling pathway;Apr-86;137/8101;0.057481703;0.463246277;0.434569728;CALM1/PRKACB/PRKAR1A/RPS6;4
NIP;hsa01250;Biosynthesis of nucleotide sugars;Feb-86;37/8101;0.0583891;0.463246277;0.434569728;NAGK/UXS1;2
NIP;hsa04371;Apelin signaling pathway;Apr-86;139/8101;0.060005994;0.463246277;0.434569728;APLNR/CALM1/PRKACB/RPS6;4
NIP;hsa04120;Ubiquitin mediated proteolysis;Apr-86;142/8101;0.063902138;0.474350484;0.444986546;FBXO2/COP1/SKP1/UBE2O;4
NIP;hsa04540;Gap junction;Mar-86;88/8101;0.066622643;0.476228523;0.446748328;PDGFRA/PRKACB/TUBB8;3
NIP;hsa04261;Adrenergic signaling in cardiomyocytes;Apr-86;150/8101;0.074927323;0.505265301;0.473987629;ATP2A1/ATP2B2/CALM1/PRKACB;4
NIP;hsa04970;Salivary secretion;Mar-86;93/8101;0.075920693;0.505265301;0.473987629;ATP2B2/CALM1/PRKACB;3
NIP;hsa05414;Dilated cardiomyopathy;Mar-86;96/8101;0.081761255;0.512250007;0.480539958;ATP2A1/LMNA/PRKACB;3
NIP;hsa04150;mTOR signaling pathway;Apr-86;155/8101;0.082278499;0.512250007;0.480539958;ATP6V1D/RPS6/WDR59/WNT5A;4
NIP;hsa04925;Aldosterone synthesis and secretion;Mar-86;98/8101;0.085760494;0.517242977;0.485223845;ATP2B2/CALM1/PRKACB;3
NIP;hsa04916;Melanogenesis;Mar-86;101/8101;0.091913251;0.521106966;0.48884864;CALM1/PRKACB/WNT5A;3
NIP;hsa00520;Amino sugar and nucleotide sugar metabolism;Feb-86;49/8101;0.095124642;0.521106966;0.48884864;NAGK/UXS1;2
NIP;hsa00270;Cysteine and methionine metabolism;Feb-86;50/8101;0.098429216;0.521106966;0.48884864;AHCY/GOT1;2
NIP;hsa05110;Vibrio cholerae infection;Feb-86;50/8101;0.098429216;0.521106966;0.48884864;ATP6V1D/PRKACB;2
NIP;hsa04014;Ras signaling pathway;May-86;232/8101;0.099901336;0.521106966;0.48884864;CALM1/EFNA4/PDGFRA/PRKACB/RALBP1;5
NIP;hsa04961;Endocrine and other factor-regulated calcium reabsorption;Feb-86;53/8101;0.108532358;0.551230133;0.517107079;ATP2B2/PRKACB;2
NIP;hsa05145;Toxoplasmosis;Mar-86;112/8101;0.115959222;0.573849482;0.538326211;HSPA1A/HSPA2/HSPA8;3
NIP;hsa04360;Axon guidance;Apr-86;182/8101;0.127691757;0.610258558;0.572481439;ABLIM1/EFNA4/EFNB1/WNT5A;4
NIP;hsa03450;Non-homologous end-joining;Jan-86;13/8101;0.129640419;0.610258558;0.572481439;DCLRE1C;1
NIP;hsa04978;Mineral absorption;Feb-86;60/8101;0.133083818;0.61155183;0.573694654;ATP2B2/FTL;2
NIP;hsa00230;Purine metabolism;Mar-86;129/8101;0.157123965;0.647149437;0.607088646;ADA2/IMPDH1/PRPS2;3
NIP;hsa04720;Long-term potentiation;Feb-86;67/8101;0.158748804;0.647149437;0.607088646;CALM1/PRKACB;2
NIP;hsa00360;Phenylalanine metabolism;Jan-86;17/8101;0.16607908;0.647149437;0.607088646;GOT1;1
NIP;hsa04924;Renin secretion;Feb-86;69/8101;0.166245715;0.647149437;0.607088646;CALM1/PRKACB;2
NIP;hsa05031;Amphetamine addiction;Feb-86;69/8101;0.166245715;0.647149437;0.607088646;CALM1/PRKACB;2
NIP;hsa05162;Measles;Mar-86;139/8101;0.183189119;0.647149437;0.607088646;HSPA1A/HSPA2/HSPA8;3
NIP;hsa01210;2-Oxocarboxylic acid metabolism;Jan-86;19/8101;0.183728787;0.647149437;0.607088646;GOT1;1
NIP;hsa01230;Biosynthesis of amino acids;Feb-86;75/8101;0.189082452;0.647149437;0.607088646;GOT1/PRPS2;2
NIP;hsa04918;Thyroid hormone synthesis;Feb-86;75/8101;0.189082452;0.647149437;0.607088646;HSPA5/PRKACB;2
NIP;hsa05214;Glioma;Feb-86;75/8101;0.189082452;0.647149437;0.607088646;CALM1/PDGFRA;2
NIP;hsa00532;Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate;Jan-86;20/8101;0.192414672;0.647149437;0.607088646;CSGALNACT2;1
NIP;hsa04971;Gastric acid secretion;Feb-86;76/8101;0.192931606;0.647149437;0.607088646;CALM1/PRKACB;2
NIP;hsa05133;Pertussis;Feb-86;76/8101;0.192931606;0.647149437;0.607088646;C1QA/CALM1;2
NIP;hsa05412;Arrhythmogenic right ventricular cardiomyopathy;Feb-86;77/8101;0.196791254;0.647149437;0.607088646;ATP2A1/LMNA;2
NIP;hsa04721;Synaptic vesicle cycle;Feb-86;78/8101;0.20066075;0.647149437;0.607088646;ATP6V1D/SLC1A1;2
NIP;hsa00770;Pantothenate and CoA biosynthesis;Jan-86;21/8101;0.201009195;0.647149437;0.607088646;VNN2;1
NIP;hsa04024;cAMP signaling pathway;Apr-86;219/8101;0.203033927;0.647149437;0.607088646;ATP2A1/ATP2B2/CALM1/PRKACB;4
NIP;hsa01521;EGFR tyrosine kinase inhibitor resistance;Feb-86;79/8101;0.204539459;0.647149437;0.607088646;PDGFRA/RPS6;2
NIP;hsa03018;RNA degradation;Feb-86;79/8101;0.204539459;0.647149437;0.607088646;C1D/PABPC5;2
NIP;hsa00220;Arginine biosynthesis;Jan-86;22/8101;0.209513305;0.652194642;0.611821535;GOT1;1
NIP;hsa05163;Human cytomegalovirus infection;Apr-86;225/8101;0.216352016;0.659329901;0.618515096;CALM1/CCL3/PDGFRA/PRKACB;4
NIP;hsa04145;Phagosome;Mar-86;152/8101;0.218637895;0.659329901;0.618515096;ATP6V1D/RILP/TUBB8;3
NIP;hsa04610;Complement and coagulation cascades;Feb-86;85/8101;0.227971186;0.662041463;0.621058804;C1QA/C3AR1;2
NIP;hsa05171;Coronavirus disease - COVID-19;Apr-86;232/8101;0.232189423;0.662041463;0.621058804;C1QA/C3AR1/RPL17/RPS6;4
NIP;hsa00563;Glycosylphosphatidylinositol (GPI)-anchor biosynthesis;Jan-86;26/8101;0.242644275;0.662041463;0.621058804;PIGT;1
NIP;hsa05161;Hepatitis B;Mar-86;162/8101;0.246813597;0.662041463;0.621058804;YWHAB/YWHAQ/YWHAZ;3
NIP;hsa05410;Hypertrophic cardiomyopathy;Feb-86;90/8101;0.247643691;0.662041463;0.621058804;ATP2A1/LMNA;2
NIP;hsa04966;Collecting duct acid secretion;Jan-86;27/8101;0.250710231;0.662041463;0.621058804;ATP6V1D;1
NIP;hsa04310;Wnt signaling pathway;Mar-86;166/8101;0.258248618;0.662041463;0.621058804;PRKACB/SKP1/WNT5A;3
NIP;hsa04912;GnRH signaling pathway;Feb-86;93/8101;0.259481264;0.662041463;0.621058804;CALM1/PRKACB;2
NIP;hsa05323;Rheumatoid arthritis;Feb-86;93/8101;0.259481264;0.662041463;0.621058804;ATP6V1D/CCL3;2
NIP;hsa04022;cGMP-PKG signaling pathway;Mar-86;167/8101;0.261119414;0.662041463;0.621058804;ATP2A1/ATP2B2/CALM1;3
NIP;hsa04744;Phototransduction;Jan-86;29/8101;0.26658828;0.662041463;0.621058804;CALM1;1
NIP;hsa00030;Pentose phosphate pathway;Jan-86;30/8101;0.274402131;0.662041463;0.621058804;PRPS2;1
NIP;hsa03015;mRNA surveillance pathway;Feb-86;97/8101;0.275277353;0.662041463;0.621058804;GSPT2/PABPC5;2
NIP;hsa04070;Phosphatidylinositol signaling system;Feb-86;97/8101;0.275277353;0.662041463;0.621058804;CALM1/PLCD3;2
NIP;hsa04713;Circadian entrainment;Feb-86;97/8101;0.275277353;0.662041463;0.621058804;CALM1/PRKACB;2
NIP;hsa01522;Endocrine resistance;Feb-86;98/8101;0.279225621;0.662041463;0.621058804;NOTCH2/PRKACB;2
NIP;hsa04750;Inflammatory mediator regulation of TRP channels;Feb-86;98/8101;0.279225621;0.662041463;0.621058804;CALM1/PRKACB;2
NIP;hsa04710;Circadian rhythm;Jan-86;31/8101;0.28213369;0.662041463;0.621058804;SKP1;1
NIP;hsa04061;Viral protein interaction with cytokine and cytokine receptor;Feb-86;100/8101;0.287118247;0.662041463;0.621058804;CCL18/CCL3;2
NIP;hsa04914;Progesterone-mediated oocyte maturation;Feb-86;102/8101;0.295002932;0.662041463;0.621058804;MAD2L1/PRKACB;2
NIP;hsa04972;Pancreatic secretion;Feb-86;102/8101;0.295002932;0.662041463;0.621058804;ATP2A1/ATP2B2;2
NIP;hsa05142;Chagas disease;Feb-86;102/8101;0.295002932;0.662041463;0.621058804;C1QA/CCL3;2
NIP;hsa04974;Protein digestion and absorption;Feb-86;103/8101;0.298941306;0.663168643;0.622116208;KCNE3/SLC1A1;2
NIP;hsa05012;Parkinson disease;Apr-86;266/8101;0.312434882;0.682351575;0.64011165;CALM1/HSPA5/PRKACB/TUBB8;4
NIP;hsa04922;Glucagon signaling pathway;Feb-86;107/8101;0.314659535;0.682351575;0.64011165;CALM1/PRKACB;2
NIP;hsa00350;Tyrosine metabolism;Jan-86;36/8101;0.319586784;0.685336103;0.642911425;GOT1;1
NIP;hsa00250;Alanine, aspartate and glutamate metabolism;Jan-86;37/8101;0.326842275;0.693183964;0.650273476;GOT1;1
NIP;hsa04062;Chemokine signaling pathway;Mar-86;192/8101;0.333811158;0.693183964;0.650273476;CCL18/CCL3/PRKACB;3
NIP;hsa05340;Primary immunodeficiency;Jan-86;38/8101;0.334021289;0.693183964;0.650273476;DCLRE1C;1
NIP;hsa04724;Glutamatergic synapse;Feb-86;114/8101;0.341976813;0.702143883;0.658678745;PRKACB/SLC1A1;2
NIP;hsa01200;Carbon metabolism;Feb-86;115/8101;0.34585438;0.702630478;0.659135218;GOT1/PRPS2;2
NIP;hsa04216;Ferroptosis;Jan-86;41/8101;0.355107389;0.713913813;0.669720075;FTL;1
NIP;hsa05205;Proteoglycans in cancer;Mar-86;205/8101;0.371732773;0.739633249;0.693847389;PRKACB/RPS6/WNT5A;3
NIP;hsa04015;Rap1 signaling pathway;Mar-86;210/8101;0.386236015;0.74498098;0.698864077;CALM1/EFNA4/PDGFRA;3
NIP;hsa05207;Chemical carcinogenesis - receptor activation;Mar-86;212/8101;0.392017914;0.74498098;0.698864077;NOTCH2/PRKACB/PTGES3;3
NIP;hsa05022;Pathways of neurodegeneration - multiple diseases;Jun-86;476/8101;0.393600893;0.74498098;0.698864077;ALS2/ATP2A1/CALM1/HSPA5/TUBB8/WNT5A;6
NIP;hsa05030;Cocaine addiction;Jan-86;49/8101;0.408165013;0.74498098;0.698864077;PRKACB;1
NIP;hsa04728;Dopaminergic synapse;Feb-86;132/8101;0.410469851;0.74498098;0.698864077;CALM1/PRKACB;2
NIP;hsa04979;Cholesterol metabolism;Jan-86;50/8101;0.414486151;0.74498098;0.698864077;LIPG;1
NIP;hsa05144;Malaria;Jan-86;50/8101;0.414486151;0.74498098;0.698864077;GYPA;1
NIP;hsa04270;Vascular smooth muscle contraction;Feb-86;134/8101;0.417880337;0.74498098;0.698864077;CALM1/PRKACB;2
NIP;hsa05206;MicroRNAs in cancer;Apr-86;310/8101;0.419206516;0.74498098;0.698864077;EFNA4/NOTCH2/PDGFRA/ST14;4
NIP;hsa05166;Human T-cell leukemia virus 1 infection;Mar-86;222/8101;0.420717026;0.74498098;0.698864077;MAD2L1/PRKACB/RAN;3
NIP;hsa00330;Arginine and proline metabolism;Jan-86;51/8101;0.420740554;0.74498098;0.698864077;GOT1;1
NIP;hsa04913;Ovarian steroidogenesis;Jan-86;51/8101;0.420740554;0.74498098;0.698864077;PRKACB;1
NIP;hsa04936;Alcoholic liver disease;Feb-86;142/8101;0.447049651;0.777231054;0.72911776;C1QA/C3AR1;2
NIP;hsa04340;Hedgehog signaling pathway;Jan-86;56/8101;0.451035638;0.777231054;0.72911776;PRKACB;1
NIP;hsa04923;Regulation of lipolysis in adipocytes;Jan-86;56/8101;0.451035638;0.777231054;0.72911776;PRKACB;1
NIP;hsa05224;Breast cancer;Feb-86;147/8101;0.464871416;0.787472759;0.738725468;NOTCH2/WNT5A;2
NIP;hsa04330;Notch signaling pathway;Jan-86;59/8101;0.468455327;0.787472759;0.738725468;NOTCH2;1
NIP;hsa05165;Human papillomavirus infection;Apr-86;331/8101;0.46921952;0.787472759;0.738725468;ATP6V1D/NOTCH2/PRKACB/WNT5A;4
NIP;hsa00561;Glycerolipid metabolism;Jan-86;61/8101;0.479763765;0.791405185;0.742414463;LIPG;1
NIP;hsa00590;Arachidonic acid metabolism;Jan-86;61/8101;0.479763765;0.791405185;0.742414463;PTGES3;1
NIP;hsa04921;Oxytocin signaling pathway;Feb-86;154/8101;0.489256831;0.792401319;0.743348933;CALM1/PRKACB;2
NIP;hsa05217;Basal cell carcinoma;Jan-86;63/8101;0.490834359;0.792401319;0.743348933;WNT5A;1
NIP;hsa04934;Cushing syndrome;Feb-86;155/8101;0.492684758;0.792401319;0.743348933;PRKACB/WNT5A;2
NIP;hsa04927;Cortisol synthesis and secretion;Jan-86;65/8101;0.501672052;0.795544275;0.746297329;PRKACB;1
NIP;hsa03010;Ribosome;Feb-86;158/8101;0.502882909;0.795544275;0.746297329;RPL17/RPS6;2
NIP;hsa00970;Aminoacyl-tRNA biosynthesis;Jan-86;66/8101;0.507005079;0.795544555;0.746297592;HARS2;1
NIP;hsa04080;Neuroactive ligand-receptor interaction;Apr-86;350/8101;0.513150775;0.798694352;0.749252405;APLNR/C3AR1/SLURP1/TACR3;4
NIP;hsa05120;Epithelial cell signaling in Helicobacter pylori infection;Jan-86;70/8101;0.527778889;0.808343859;0.758304575;ATP6V1D;1
NIP;hsa05230;Central carbon metabolism in cancer;Jan-86;70/8101;0.527778889;0.808343859;0.758304575;PDGFRA;1
NIP;hsa05218;Melanoma;Jan-86;72/8101;0.537838925;0.808343859;0.758304575;PDGFRA;1
NIP;hsa00562;Inositol phosphate metabolism;Jan-86;73/8101;0.542789212;0.808343859;0.758304575;PLCD3;1
NIP;hsa04115;p53 signaling pathway;Jan-86;73/8101;0.542789212;0.808343859;0.758304575;COP1;1
NIP;hsa05014;Amyotrophic lateral sclerosis;Apr-86;364/8101;0.54448032;0.808343859;0.758304575;ALS2/HSPA5/SRSF3/TUBB8;4
NIP;hsa05212;Pancreatic cancer;Jan-86;76/8101;0.55732778;0.821101234;0.770272224;RALBP1;1
NIP;hsa00983;Drug metabolism - other enzymes;Jan-86;80/8101;0.576003967;0.83231654;0.780793263;IMPDH1;1
NIP;hsa05010;Alzheimer disease;Apr-86;384/8101;0.587432955;0.83231654;0.780793263;ATP2A1/CALM1/TUBB8/WNT5A;4
NIP;hsa05034;Alcoholism;Feb-86;187/8101;0.594523372;0.83231654;0.780793263;CALM1/PRKACB;2
NIP;hsa04742;Taste transduction;Jan-86;86/8101;0.602567411;0.83231654;0.780793263;PRKACB;1
NIP;hsa04911;Insulin secretion;Jan-86;86/8101;0.602567411;0.83231654;0.780793263;PRKACB;1
NIP;hsa04260;Cardiac muscle contraction;Jan-86;87/8101;0.606831816;0.83231654;0.780793263;ATP2A1;1
NIP;hsa04060;Cytokine-cytokine receptor interaction;Mar-86;295/8101;0.611432354;0.83231654;0.780793263;CCL18/CCL3/EDA;3
NIP;hsa04211;Longevity regulating pathway;Jan-86;89/8101;0.615225409;0.83231654;0.780793263;PRKACB;1
NIP;hsa04727;GABAergic synapse;Jan-86;89/8101;0.615225409;0.83231654;0.780793263;PRKACB;1
NIP;hsa04976;Bile secretion;Jan-86;89/8101;0.615225409;0.83231654;0.780793263;PRKACB;1
NIP;hsa05130;Pathogenic Escherichia coli infection;Feb-86;197/8101;0.623112351;0.83231654;0.780793263;BRK1/TUBB8;2
NIP;hsa05032;Morphine addiction;Jan-86;91/8101;0.62344185;0.83231654;0.780793263;PRKACB;1
NIP;hsa04658;Th1 and Th2 cell differentiation;Jan-86;92/8101;0.627484796;0.83231654;0.780793263;NOTCH2;1
NIP;hsa04350;TGF-beta signaling pathway;Jan-86;94/8101;0.635442415;0.83231654;0.780793263;SKP1;1
NIP;hsa04666;Fc gamma R-mediated phagocytosis;Jan-86;97/8101;0.64706484;0.83231654;0.780793263;AMPH;1
NIP;hsa05215;Prostate cancer;Jan-86;97/8101;0.64706484;0.83231654;0.780793263;PDGFRA;1
NIP;hsa05231;Choline metabolism in cancer;Jan-86;98/8101;0.650856997;0.83231654;0.780793263;PDGFRA;1
NIP;hsa04640;Hematopoietic cell lineage;Jan-86;99/8101;0.654608877;0.83231654;0.780793263;GYPA;1
NIP;hsa04933;AGE-RAGE signaling pathway in diabetic complications;Jan-86;100/8101;0.658320904;0.83231654;0.780793263;PLCD3;1
NIP;hsa05170;Human immunodeficiency virus 1 infection;Feb-86;212/8101;0.663085722;0.83231654;0.780793263;CALM1/SKP1;2
NIP;hsa05146;Amoebiasis;Jan-86;102/8101;0.665627065;0.83231654;0.780793263;PRKACB;1
NIP;hsa04064;NF-kappa B signaling pathway;Jan-86;104/8101;0.672778776;0.83231654;0.780793263;EDA;1
NIP;hsa04620;Toll-like receptor signaling pathway;Jan-86;104/8101;0.672778776;0.83231654;0.780793263;CCL3;1
NIP;hsa04625;C-type lectin receptor signaling pathway;Jan-86;104/8101;0.672778776;0.83231654;0.780793263;CALM1;1
NIP;hsa04810;Regulation of actin cytoskeleton;Feb-86;218/8101;0.678110305;0.83231654;0.780793263;BRK1/PDGFRA;2
NIP;hsa04928;Parathyroid hormone synthesis, secretion and action;Jan-86;106/8101;0.679779264;0.83231654;0.780793263;PRKACB;1
NIP;hsa03013;Nucleocytoplasmic transport;Jan-86;108/8101;0.68663169;0.83231654;0.780793263;RAN;1
NIP;hsa03008;Ribosome biogenesis in eukaryotes;Jan-86;109/8101;0.690003349;0.83231654;0.780793263;RAN;1
NIP;hsa04066;HIF-1 signaling pathway;Jan-86;109/8101;0.690003349;0.83231654;0.780793263;RPS6;1
NIP;hsa04725;Cholinergic synapse;Jan-86;113/8101;0.70313514;0.841950977;0.789831295;PRKACB;1
NIP;hsa04726;Serotonergic synapse;Jan-86;115/8101;0.709493309;0.841950977;0.789831295;PRKACB;1
NIP;hsa04714;Thermogenesis;Feb-86;232/8101;0.711077768;0.841950977;0.789831295;PRKACB/RPS6;2
NIP;hsa04722;Neurotrophin signaling pathway;Jan-86;119/8101;0.721808582;0.844297311;0.792032383;CALM1;1
NIP;hsa04935;Growth hormone synthesis, secretion and action;Jan-86;119/8101;0.721808582;0.844297311;0.792032383;PRKACB;1
NIP;hsa04611;Platelet activation;Jan-86;124/8101;0.736479212;0.856267999;0.803262044;PRKACB;1
NIP;hsa05131;Shigellosis;Feb-86;247/8101;0.743264631;0.858982478;0.805808488;PLCD3/SKP1;2
NIP;hsa04926;Relaxin signaling pathway;Jan-86;129/8101;0.7503847;0.861457426;0.808130228;PRKACB;1
NIP;hsa04650;Natural killer cell mediated cytotoxicity;Jan-86;131/8101;0.755741563;0.861457426;0.808130228;HCST;1
NIP;hsa00190;Oxidative phosphorylation;Jan-86;134/8101;0.763564507;0.861457426;0.808130228;ATP6V1D;1
NIP;hsa04210;Apoptosis;Jan-86;136/8101;0.768641693;0.861457426;0.808130228;LMNA;1
NIP;hsa05322;Systemic lupus erythematosus;Jan-86;136/8101;0.768641693;0.861457426;0.808130228;C1QA;1
NIP;hsa05418;Fluid shear stress and atherosclerosis;Jan-86;139/8101;0.776056081;0.861457426;0.808130228;CALM1;1
NIP;hsa04140;Autophagy - animal;Jan-86;141/8101;0.780868028;0.861457426;0.808130228;PRKACB;1
NIP;hsa04550;Signaling pathways regulating pluripotency of stem cells;Jan-86;143/8101;0.785577757;0.861457426;0.808130228;WNT5A;1
NIP;hsa05017;Spinocerebellar ataxia;Jan-86;143/8101;0.785577757;0.861457426;0.808130228;ATP2A1;1
NIP;hsa04072;Phospholipase D signaling pathway;Jan-86;148/8101;0.796918845;0.861615473;0.808278492;PDGFRA;1
NIP;hsa04723;Retrograde endocannabinoid signaling;Jan-86;148/8101;0.796918845;0.861615473;0.808278492;PRKACB;1
NIP;hsa05226;Gastric cancer;Jan-86;149/8101;0.799114869;0.861615473;0.808278492;WNT5A;1
NIP;hsa04218;Cellular senescence;Jan-86;156/8101;0.813843485;0.87262107;0.818602803;CALM1;1
NIP;hsa04217;Necroptosis;Jan-86;159/8101;0.819824138;0.87417712;0.820062529;FTL;1
NIP;hsa04630;JAK-STAT signaling pathway;Jan-86;162/8101;0.825614815;0.875514611;0.821317224;PDGFRA;1
NIP;hsa05225;Hepatocellular carcinoma;Jan-86;168/8101;0.836649913;0.879430468;0.824990676;WNT5A;1
NIP;hsa04530;Tight junction;Jan-86;169/8101;0.838420757;0.879430468;0.824990676;PRKACB;1
NIP;hsa05152;Tuberculosis;Jan-86;180/8101;0.856690787;0.893736875;0.838411467;CALM1;1
NIP;hsa04621;NOD-like receptor signaling pathway;Jan-86;184/8101;0.862815056;0.89528659;0.83986525;DEFA1;1
NIP;hsa05202;Transcriptional misregulation in cancer;Jan-86;192/8101;0.874297995;0.900341912;0.84460763;DEFA1;1
NIP;hsa05167;Kaposi sarcoma-associated herpesvirus infection;Jan-86;194/8101;0.877016992;0.900341912;0.84460763;CALM1;1
NIP;hsa04510;Focal adhesion;Jan-86;201/8101;0.886083601;0.902580205;0.846707365;PDGFRA;1
NIP;hsa05415;Diabetic cardiomyopathy;Jan-86;203/8101;0.888550461;0.902580205;0.846707365;ATP2A1;1
NIP;hsa04740;Olfactory transduction;Feb-86;441/8101;0.952507294;0.962481192;0.902900273;CALM1/PRKACB;2
NIP;hsa05016;Huntington disease;Jan-86;306/8101;0.964180766;0.969202541;0.909205547;TUBB8;1
NIP;hsa05168;Herpes simplex virus 1 infection;Feb-86;495/8101;0.971439892;0.971439892;0.911304398;SRSF3/SRSF6;2
VIP;hsa04114;Oocyte meiosis;Sept-86;131/8101;9.22E-06;0.001155639;0.001084101;CALM1/MAD2L1/PRKACB/SKP1/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;9
VIP;hsa04141;Protein processing in endoplasmic reticulum;Oct-86;171/8101;1.20E-05;0.001155639;0.001084101;BAG1/BAG2/DNAJB11/FBXO2/FBXO6/HSPA1A/HSPA2/HSPA5/HSPA8/SKP1;10
VIP;hsa03060;Protein export;Apr-86;23/8101;8.99E-05;0.005782139;0.005424204;HSPA5/SRP14/SRP68/SRP9;4
VIP;hsa04110;Cell cycle;Jul-86;126/8101;0.000361617;0.017448037;0.016367943;MAD2L1/SKP1/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
VIP;hsa04915;Estrogen signaling pathway;Jun-86;138/8101;0.003375599;0.126939109;0.119081139;CALM1/HSPA1A/HSPA2/HSPA8/KRT38/PRKACB;6
VIP;hsa04213;Longevity regulating pathway - multiple species;Apr-86;62/8101;0.004135478;0.126939109;0.119081139;HSPA1A/HSPA2/HSPA8/PRKACB;4
VIP;hsa03040;Spliceosome;Jun-86;147/8101;0.004604009;0.126939109;0.119081139;HSPA1A/HSPA2/HSPA8/PPIE/SRSF3/SRSF6;6
VIP;hsa05203;Viral carcinogenesis;Jul-86;204/8101;0.005798373;0.135652032;0.127254701;HPN/PRKACB/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;7
VIP;hsa04390;Hippo signaling pathway;Jun-86;157/8101;0.006325742;0.135652032;0.127254701;WNT5A/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;6
VIP;hsa04612;Antigen processing and presentation;Apr-86;78/8101;0.00930491;0.179584757;0.168467839;HSPA1A/HSPA2/HSPA5/HSPA8;4
VIP;hsa04962;Vasopressin-regulated water reabsorption;Mar-86;44/8101;0.011182747;0.196206387;0.184060532;DYNLL1/DYNLL2/PRKACB;3
VIP;hsa04020;Calcium signaling pathway;Jul-86;240/8101;0.013546735;0.21787666;0.20438934;ATP2A1/ATP2B2/CALM1/PDGFRA/PLCD3/PRKACB/TACR3;7
VIP;hsa05150;Staphylococcus aureus infection;Apr-86;96/8101;0.018779611;0.278805;0.261546005;C1QA/C3AR1/DEFA1/KRT38;4
VIP;hsa05134;Legionellosis;Mar-86;57/8101;0.02239489;0.299726554;0.281172442;HSPA1A/HSPA2/HSPA8;3
VIP;hsa05160;Hepatitis C;May-86;157/8101;0.02543475;0.299726554;0.281172442;YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;5
VIP;hsa05020;Prion disease;Jul-86;273/8101;0.025542416;0.299726554;0.281172442;C1QA/HSPA1A/HSPA2/HSPA5/HSPA8/PRKACB/TUBB8;7
VIP;hsa05417;Lipid and atherosclerosis;Jun-86;215/8101;0.026400785;0.299726554;0.281172442;CALM1/CCL3/HSPA1A/HSPA2/HSPA5/HSPA8;6
VIP;hsa04151;PI3K-Akt signaling pathway;Aug-86;354/8101;0.033708304;0.361427922;0.339054282;EFNA4/PDGFRA/RPS6/YWHAB/YWHAG/YWHAH/YWHAQ/YWHAZ;8
VIP;hsa04010;MAPK signaling pathway;Jul-86;294/8101;0.036164775;0.367357974;0.344617243;DUSP16/EFNA4/HSPA1A/HSPA2/HSPA8/PDGFRA/PRKACB;7
VIP;hsa04919;Thyroid hormone signaling pathway;Apr-86;121/8101;0.039420721;0.380409955;0.356861262;ATP2A1/NOTCH2/PLCD3/PRKACB;4
VIP;hsa05132;Salmonella infection;Jun-86;249/8101;0.048541654;0.446120919;0.418504489;BRK1/DYNLL1/DYNLL2/RILP/SKP1/TUBB8;6
VIP;hsa04144;Endocytosis;Jun-86;252/8101;0.05091964;0.446704116;0.419051584;AMPH/HSPA1A/HSPA2/HSPA8/PDGFRA/VPS37D;6
VIP;hsa04910;Insulin signaling pathway;Apr-86;137/8101;0.057481703;0.463246277;0.434569728;CALM1/PRKACB/PRKAR1A/RPS6;4
VIP;hsa01250;Biosynthesis of nucleotide sugars;Feb-86;37/8101;0.0583891;0.463246277;0.434569728;NAGK/UXS1;2
VIP;hsa04371;Apelin signaling pathway;Apr-86;139/8101;0.060005994;0.463246277;0.434569728;APLNR/CALM1/PRKACB/RPS6;4
VIP;hsa04120;Ubiquitin mediated proteolysis;Apr-86;142/8101;0.063902138;0.474350484;0.444986546;FBXO2/COP1/SKP1/UBE2O;4
VIP;hsa04540;Gap junction;Mar-86;88/8101;0.066622643;0.476228523;0.446748328;PDGFRA/PRKACB/TUBB8;3
VIP;hsa04261;Adrenergic signaling in cardiomyocytes;Apr-86;150/8101;0.074927323;0.505265301;0.473987629;ATP2A1/ATP2B2/CALM1/PRKACB;4
VIP;hsa04970;Salivary secretion;Mar-86;93/8101;0.075920693;0.505265301;0.473987629;ATP2B2/CALM1/PRKACB;3
VIP;hsa05414;Dilated cardiomyopathy;Mar-86;96/8101;0.081761255;0.512250007;0.480539958;ATP2A1/LMNA/PRKACB;3
VIP;hsa04150;mTOR signaling pathway;Apr-86;155/8101;0.082278499;0.512250007;0.480539958;ATP6V1D/RPS6/WDR59/WNT5A;4
VIP;hsa04925;Aldosterone synthesis and secretion;Mar-86;98/8101;0.085760494;0.517242977;0.485223845;ATP2B2/CALM1/PRKACB;3
VIP;hsa04916;Melanogenesis;Mar-86;101/8101;0.091913251;0.521106966;0.48884864;CALM1/PRKACB/WNT5A;3
VIP;hsa00520;Amino sugar and nucleotide sugar metabolism;Feb-86;49/8101;0.095124642;0.521106966;0.48884864;NAGK/UXS1;2
VIP;hsa00270;Cysteine and methionine metabolism;Feb-86;50/8101;0.098429216;0.521106966;0.48884864;AHCY/GOT1;2
VIP;hsa05110;Vibrio cholerae infection;Feb-86;50/8101;0.098429216;0.521106966;0.48884864;ATP6V1D/PRKACB;2
VIP;hsa04014;Ras signaling pathway;May-86;232/8101;0.099901336;0.521106966;0.48884864;CALM1/EFNA4/PDGFRA/PRKACB/RALBP1;5
VIP;hsa04961;Endocrine and other factor-regulated calcium reabsorption;Feb-86;53/8101;0.108532358;0.551230133;0.517107079;ATP2B2/PRKACB;2
VIP;hsa05145;Toxoplasmosis;Mar-86;112/8101;0.115959222;0.573849482;0.538326211;HSPA1A/HSPA2/HSPA8;3
VIP;hsa04360;Axon guidance;Apr-86;182/8101;0.127691757;0.610258558;0.572481439;ABLIM1/EFNA4/EFNB1/WNT5A;4
VIP;hsa03450;Non-homologous end-joining;Jan-86;13/8101;0.129640419;0.610258558;0.572481439;DCLRE1C;1
VIP;hsa04978;Mineral absorption;Feb-86;60/8101;0.133083818;0.61155183;0.573694654;ATP2B2/FTL;2
VIP;hsa00230;Purine metabolism;Mar-86;129/8101;0.157123965;0.647149437;0.607088646;ADA2/IMPDH1/PRPS2;3
VIP;hsa04720;Long-term potentiation;Feb-86;67/8101;0.158748804;0.647149437;0.607088646;CALM1/PRKACB;2
VIP;hsa00360;Phenylalanine metabolism;Jan-86;17/8101;0.16607908;0.647149437;0.607088646;GOT1;1
VIP;hsa04924;Renin secretion;Feb-86;69/8101;0.166245715;0.647149437;0.607088646;CALM1/PRKACB;2
VIP;hsa05031;Amphetamine addiction;Feb-86;69/8101;0.166245715;0.647149437;0.607088646;CALM1/PRKACB;2
VIP;hsa05162;Measles;Mar-86;139/8101;0.183189119;0.647149437;0.607088646;HSPA1A/HSPA2/HSPA8;3
VIP;hsa01210;2-Oxocarboxylic acid metabolism;Jan-86;19/8101;0.183728787;0.647149437;0.607088646;GOT1;1
VIP;hsa01230;Biosynthesis of amino acids;Feb-86;75/8101;0.189082452;0.647149437;0.607088646;GOT1/PRPS2;2
VIP;hsa04918;Thyroid hormone synthesis;Feb-86;75/8101;0.189082452;0.647149437;0.607088646;HSPA5/PRKACB;2
VIP;hsa05214;Glioma;Feb-86;75/8101;0.189082452;0.647149437;0.607088646;CALM1/PDGFRA;2
VIP;hsa00532;Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate;Jan-86;20/8101;0.192414672;0.647149437;0.607088646;CSGALNACT2;1
VIP;hsa04971;Gastric acid secretion;Feb-86;76/8101;0.192931606;0.647149437;0.607088646;CALM1/PRKACB;2
VIP;hsa05133;Pertussis;Feb-86;76/8101;0.192931606;0.647149437;0.607088646;C1QA/CALM1;2
VIP;hsa05412;Arrhythmogenic right ventricular cardiomyopathy;Feb-86;77/8101;0.196791254;0.647149437;0.607088646;ATP2A1/LMNA;2
VIP;hsa04721;Synaptic vesicle cycle;Feb-86;78/8101;0.20066075;0.647149437;0.607088646;ATP6V1D/SLC1A1;2
VIP;hsa00770;Pantothenate and CoA biosynthesis;Jan-86;21/8101;0.201009195;0.647149437;0.607088646;VNN2;1
VIP;hsa04024;cAMP signaling pathway;Apr-86;219/8101;0.203033927;0.647149437;0.607088646;ATP2A1/ATP2B2/CALM1/PRKACB;4
VIP;hsa01521;EGFR tyrosine kinase inhibitor resistance;Feb-86;79/8101;0.204539459;0.647149437;0.607088646;PDGFRA/RPS6;2
VIP;hsa03018;RNA degradation;Feb-86;79/8101;0.204539459;0.647149437;0.607088646;C1D/PABPC5;2
VIP;hsa00220;Arginine biosynthesis;Jan-86;22/8101;0.209513305;0.652194642;0.611821535;GOT1;1
VIP;hsa05163;Human cytomegalovirus infection;Apr-86;225/8101;0.216352016;0.659329901;0.618515096;CALM1/CCL3/PDGFRA/PRKACB;4
VIP;hsa04145;Phagosome;Mar-86;152/8101;0.218637895;0.659329901;0.618515096;ATP6V1D/RILP/TUBB8;3
VIP;hsa04610;Complement and coagulation cascades;Feb-86;85/8101;0.227971186;0.662041463;0.621058804;C1QA/C3AR1;2
VIP;hsa05171;Coronavirus disease - COVID-19;Apr-86;232/8101;0.232189423;0.662041463;0.621058804;C1QA/C3AR1/RPL17/RPS6;4
VIP;hsa00563;Glycosylphosphatidylinositol (GPI)-anchor biosynthesis;Jan-86;26/8101;0.242644275;0.662041463;0.621058804;PIGT;1
VIP;hsa05161;Hepatitis B;Mar-86;162/8101;0.246813597;0.662041463;0.621058804;YWHAB/YWHAQ/YWHAZ;3
VIP;hsa05410;Hypertrophic cardiomyopathy;Feb-86;90/8101;0.247643691;0.662041463;0.621058804;ATP2A1/LMNA;2
VIP;hsa04966;Collecting duct acid secretion;Jan-86;27/8101;0.250710231;0.662041463;0.621058804;ATP6V1D;1
VIP;hsa04310;Wnt signaling pathway;Mar-86;166/8101;0.258248618;0.662041463;0.621058804;PRKACB/SKP1/WNT5A;3
VIP;hsa04912;GnRH signaling pathway;Feb-86;93/8101;0.259481264;0.662041463;0.621058804;CALM1/PRKACB;2
VIP;hsa05323;Rheumatoid arthritis;Feb-86;93/8101;0.259481264;0.662041463;0.621058804;ATP6V1D/CCL3;2
VIP;hsa04022;cGMP-PKG signaling pathway;Mar-86;167/8101;0.261119414;0.662041463;0.621058804;ATP2A1/ATP2B2/CALM1;3
VIP;hsa04744;Phototransduction;Jan-86;29/8101;0.26658828;0.662041463;0.621058804;CALM1;1
VIP;hsa00030;Pentose phosphate pathway;Jan-86;30/8101;0.274402131;0.662041463;0.621058804;PRPS2;1
VIP;hsa03015;mRNA surveillance pathway;Feb-86;97/8101;0.275277353;0.662041463;0.621058804;GSPT2/PABPC5;2
VIP;hsa04070;Phosphatidylinositol signaling system;Feb-86;97/8101;0.275277353;0.662041463;0.621058804;CALM1/PLCD3;2
VIP;hsa04713;Circadian entrainment;Feb-86;97/8101;0.275277353;0.662041463;0.621058804;CALM1/PRKACB;2
VIP;hsa01522;Endocrine resistance;Feb-86;98/8101;0.279225621;0.662041463;0.621058804;NOTCH2/PRKACB;2
VIP;hsa04750;Inflammatory mediator regulation of TRP channels;Feb-86;98/8101;0.279225621;0.662041463;0.621058804;CALM1/PRKACB;2
VIP;hsa04710;Circadian rhythm;Jan-86;31/8101;0.28213369;0.662041463;0.621058804;SKP1;1
VIP;hsa04061;Viral protein interaction with cytokine and cytokine receptor;Feb-86;100/8101;0.287118247;0.662041463;0.621058804;CCL18/CCL3;2
VIP;hsa04914;Progesterone-mediated oocyte maturation;Feb-86;102/8101;0.295002932;0.662041463;0.621058804;MAD2L1/PRKACB;2
VIP;hsa04972;Pancreatic secretion;Feb-86;102/8101;0.295002932;0.662041463;0.621058804;ATP2A1/ATP2B2;2
VIP;hsa05142;Chagas disease;Feb-86;102/8101;0.295002932;0.662041463;0.621058804;C1QA/CCL3;2
VIP;hsa04974;Protein digestion and absorption;Feb-86;103/8101;0.298941306;0.663168643;0.622116208;KCNE3/SLC1A1;2
VIP;hsa05012;Parkinson disease;Apr-86;266/8101;0.312434882;0.682351575;0.64011165;CALM1/HSPA5/PRKACB/TUBB8;4
VIP;hsa04922;Glucagon signaling pathway;Feb-86;107/8101;0.314659535;0.682351575;0.64011165;CALM1/PRKACB;2
VIP;hsa00350;Tyrosine metabolism;Jan-86;36/8101;0.319586784;0.685336103;0.642911425;GOT1;1
VIP;hsa00250;Alanine, aspartate and glutamate metabolism;Jan-86;37/8101;0.326842275;0.693183964;0.650273476;GOT1;1
VIP;hsa04062;Chemokine signaling pathway;Mar-86;192/8101;0.333811158;0.693183964;0.650273476;CCL18/CCL3/PRKACB;3
VIP;hsa05340;Primary immunodeficiency;Jan-86;38/8101;0.334021289;0.693183964;0.650273476;DCLRE1C;1
VIP;hsa04724;Glutamatergic synapse;Feb-86;114/8101;0.341976813;0.702143883;0.658678745;PRKACB/SLC1A1;2
VIP;hsa01200;Carbon metabolism;Feb-86;115/8101;0.34585438;0.702630478;0.659135218;GOT1/PRPS2;2
VIP;hsa04216;Ferroptosis;Jan-86;41/8101;0.355107389;0.713913813;0.669720075;FTL;1
VIP;hsa05205;Proteoglycans in cancer;Mar-86;205/8101;0.371732773;0.739633249;0.693847389;PRKACB/RPS6/WNT5A;3
VIP;hsa04015;Rap1 signaling pathway;Mar-86;210/8101;0.386236015;0.74498098;0.698864077;CALM1/EFNA4/PDGFRA;3
VIP;hsa05207;Chemical carcinogenesis - receptor activation;Mar-86;212/8101;0.392017914;0.74498098;0.698864077;NOTCH2/PRKACB/PTGES3;3
VIP;hsa05022;Pathways of neurodegeneration - multiple diseases;Jun-86;476/8101;0.393600893;0.74498098;0.698864077;ALS2/ATP2A1/CALM1/HSPA5/TUBB8/WNT5A;6
VIP;hsa05030;Cocaine addiction;Jan-86;49/8101;0.408165013;0.74498098;0.698864077;PRKACB;1
VIP;hsa04728;Dopaminergic synapse;Feb-86;132/8101;0.410469851;0.74498098;0.698864077;CALM1/PRKACB;2
VIP;hsa04979;Cholesterol metabolism;Jan-86;50/8101;0.414486151;0.74498098;0.698864077;LIPG;1
VIP;hsa05144;Malaria;Jan-86;50/8101;0.414486151;0.74498098;0.698864077;GYPA;1
VIP;hsa04270;Vascular smooth muscle contraction;Feb-86;134/8101;0.417880337;0.74498098;0.698864077;CALM1/PRKACB;2
VIP;hsa05206;MicroRNAs in cancer;Apr-86;310/8101;0.419206516;0.74498098;0.698864077;EFNA4/NOTCH2/PDGFRA/ST14;4
VIP;hsa05166;Human T-cell leukemia virus 1 infection;Mar-86;222/8101;0.420717026;0.74498098;0.698864077;MAD2L1/PRKACB/RAN;3
VIP;hsa00330;Arginine and proline metabolism;Jan-86;51/8101;0.420740554;0.74498098;0.698864077;GOT1;1
VIP;hsa04913;Ovarian steroidogenesis;Jan-86;51/8101;0.420740554;0.74498098;0.698864077;PRKACB;1
VIP;hsa04936;Alcoholic liver disease;Feb-86;142/8101;0.447049651;0.777231054;0.72911776;C1QA/C3AR1;2
VIP;hsa04340;Hedgehog signaling pathway;Jan-86;56/8101;0.451035638;0.777231054;0.72911776;PRKACB;1
VIP;hsa04923;Regulation of lipolysis in adipocytes;Jan-86;56/8101;0.451035638;0.777231054;0.72911776;PRKACB;1
VIP;hsa05224;Breast cancer;Feb-86;147/8101;0.464871416;0.787472759;0.738725468;NOTCH2/WNT5A;2
VIP;hsa04330;Notch signaling pathway;Jan-86;59/8101;0.468455327;0.787472759;0.738725468;NOTCH2;1
VIP;hsa05165;Human papillomavirus infection;Apr-86;331/8101;0.46921952;0.787472759;0.738725468;ATP6V1D/NOTCH2/PRKACB/WNT5A;4
VIP;hsa00561;Glycerolipid metabolism;Jan-86;61/8101;0.479763765;0.791405185;0.742414463;LIPG;1
VIP;hsa00590;Arachidonic acid metabolism;Jan-86;61/8101;0.479763765;0.791405185;0.742414463;PTGES3;1
VIP;hsa04921;Oxytocin signaling pathway;Feb-86;154/8101;0.489256831;0.792401319;0.743348933;CALM1/PRKACB;2
VIP;hsa05217;Basal cell carcinoma;Jan-86;63/8101;0.490834359;0.792401319;0.743348933;WNT5A;1
VIP;hsa04934;Cushing syndrome;Feb-86;155/8101;0.492684758;0.792401319;0.743348933;PRKACB/WNT5A;2
VIP;hsa04927;Cortisol synthesis and secretion;Jan-86;65/8101;0.501672052;0.795544275;0.746297329;PRKACB;1
VIP;hsa03010;Ribosome;Feb-86;158/8101;0.502882909;0.795544275;0.746297329;RPL17/RPS6;2
VIP;hsa00970;Aminoacyl-tRNA biosynthesis;Jan-86;66/8101;0.507005079;0.795544555;0.746297592;HARS2;1
VIP;hsa04080;Neuroactive ligand-receptor interaction;Apr-86;350/8101;0.513150775;0.798694352;0.749252405;APLNR/C3AR1/SLURP1/TACR3;4
VIP;hsa05120;Epithelial cell signaling in Helicobacter pylori infection;Jan-86;70/8101;0.527778889;0.808343859;0.758304575;ATP6V1D;1
VIP;hsa05230;Central carbon metabolism in cancer;Jan-86;70/8101;0.527778889;0.808343859;0.758304575;PDGFRA;1
VIP;hsa05218;Melanoma;Jan-86;72/8101;0.537838925;0.808343859;0.758304575;PDGFRA;1
VIP;hsa00562;Inositol phosphate metabolism;Jan-86;73/8101;0.542789212;0.808343859;0.758304575;PLCD3;1
VIP;hsa04115;p53 signaling pathway;Jan-86;73/8101;0.542789212;0.808343859;0.758304575;COP1;1
VIP;hsa05014;Amyotrophic lateral sclerosis;Apr-86;364/8101;0.54448032;0.808343859;0.758304575;ALS2/HSPA5/SRSF3/TUBB8;4
VIP;hsa05212;Pancreatic cancer;Jan-86;76/8101;0.55732778;0.821101234;0.770272224;RALBP1;1
VIP;hsa00983;Drug metabolism - other enzymes;Jan-86;80/8101;0.576003967;0.83231654;0.780793263;IMPDH1;1
VIP;hsa05010;Alzheimer disease;Apr-86;384/8101;0.587432955;0.83231654;0.780793263;ATP2A1/CALM1/TUBB8/WNT5A;4
VIP;hsa05034;Alcoholism;Feb-86;187/8101;0.594523372;0.83231654;0.780793263;CALM1/PRKACB;2
VIP;hsa04742;Taste transduction;Jan-86;86/8101;0.602567411;0.83231654;0.780793263;PRKACB;1
VIP;hsa04911;Insulin secretion;Jan-86;86/8101;0.602567411;0.83231654;0.780793263;PRKACB;1
VIP;hsa04260;Cardiac muscle contraction;Jan-86;87/8101;0.606831816;0.83231654;0.780793263;ATP2A1;1
VIP;hsa04060;Cytokine-cytokine receptor interaction;Mar-86;295/8101;0.611432354;0.83231654;0.780793263;CCL18/CCL3/EDA;3
VIP;hsa04211;Longevity regulating pathway;Jan-86;89/8101;0.615225409;0.83231654;0.780793263;PRKACB;1
VIP;hsa04727;GABAergic synapse;Jan-86;89/8101;0.615225409;0.83231654;0.780793263;PRKACB;1
VIP;hsa04976;Bile secretion;Jan-86;89/8101;0.615225409;0.83231654;0.780793263;PRKACB;1
VIP;hsa05130;Pathogenic Escherichia coli infection;Feb-86;197/8101;0.623112351;0.83231654;0.780793263;BRK1/TUBB8;2
VIP;hsa05032;Morphine addiction;Jan-86;91/8101;0.62344185;0.83231654;0.780793263;PRKACB;1
VIP;hsa04658;Th1 and Th2 cell differentiation;Jan-86;92/8101;0.627484796;0.83231654;0.780793263;NOTCH2;1
VIP;hsa04350;TGF-beta signaling pathway;Jan-86;94/8101;0.635442415;0.83231654;0.780793263;SKP1;1
VIP;hsa04666;Fc gamma R-mediated phagocytosis;Jan-86;97/8101;0.64706484;0.83231654;0.780793263;AMPH;1
VIP;hsa05215;Prostate cancer;Jan-86;97/8101;0.64706484;0.83231654;0.780793263;PDGFRA;1
VIP;hsa05231;Choline metabolism in cancer;Jan-86;98/8101;0.650856997;0.83231654;0.780793263;PDGFRA;1
VIP;hsa04640;Hematopoietic cell lineage;Jan-86;99/8101;0.654608877;0.83231654;0.780793263;GYPA;1
VIP;hsa04933;AGE-RAGE signaling pathway in diabetic complications;Jan-86;100/8101;0.658320904;0.83231654;0.780793263;PLCD3;1
VIP;hsa05170;Human immunodeficiency virus 1 infection;Feb-86;212/8101;0.663085722;0.83231654;0.780793263;CALM1/SKP1;2
VIP;hsa05146;Amoebiasis;Jan-86;102/8101;0.665627065;0.83231654;0.780793263;PRKACB;1
VIP;hsa04064;NF-kappa B signaling pathway;Jan-86;104/8101;0.672778776;0.83231654;0.780793263;EDA;1
VIP;hsa04620;Toll-like receptor signaling pathway;Jan-86;104/8101;0.672778776;0.83231654;0.780793263;CCL3;1
VIP;hsa04625;C-type lectin receptor signaling pathway;Jan-86;104/8101;0.672778776;0.83231654;0.780793263;CALM1;1
VIP;hsa04810;Regulation of actin cytoskeleton;Feb-86;218/8101;0.678110305;0.83231654;0.780793263;BRK1/PDGFRA;2
VIP;hsa04928;Parathyroid hormone synthesis, secretion and action;Jan-86;106/8101;0.679779264;0.83231654;0.780793263;PRKACB;1
VIP;hsa03013;Nucleocytoplasmic transport;Jan-86;108/8101;0.68663169;0.83231654;0.780793263;RAN;1
VIP;hsa03008;Ribosome biogenesis in eukaryotes;Jan-86;109/8101;0.690003349;0.83231654;0.780793263;RAN;1
VIP;hsa04066;HIF-1 signaling pathway;Jan-86;109/8101;0.690003349;0.83231654;0.780793263;RPS6;1
VIP;hsa04725;Cholinergic synapse;Jan-86;113/8101;0.70313514;0.841950977;0.789831295;PRKACB;1
VIP;hsa04726;Serotonergic synapse;Jan-86;115/8101;0.709493309;0.841950977;0.789831295;PRKACB;1
VIP;hsa04714;Thermogenesis;Feb-86;232/8101;0.711077768;0.841950977;0.789831295;PRKACB/RPS6;2
VIP;hsa04722;Neurotrophin signaling pathway;Jan-86;119/8101;0.721808582;0.844297311;0.792032383;CALM1;1
VIP;hsa04935;Growth hormone synthesis, secretion and action;Jan-86;119/8101;0.721808582;0.844297311;0.792032383;PRKACB;1
VIP;hsa04611;Platelet activation;Jan-86;124/8101;0.736479212;0.856267999;0.803262044;PRKACB;1
VIP;hsa05131;Shigellosis;Feb-86;247/8101;0.743264631;0.858982478;0.805808488;PLCD3/SKP1;2
VIP;hsa04926;Relaxin signaling pathway;Jan-86;129/8101;0.7503847;0.861457426;0.808130228;PRKACB;1
VIP;hsa04650;Natural killer cell mediated cytotoxicity;Jan-86;131/8101;0.755741563;0.861457426;0.808130228;HCST;1
VIP;hsa00190;Oxidative phosphorylation;Jan-86;134/8101;0.763564507;0.861457426;0.808130228;ATP6V1D;1
VIP;hsa04210;Apoptosis;Jan-86;136/8101;0.768641693;0.861457426;0.808130228;LMNA;1
VIP;hsa05322;Systemic lupus erythematosus;Jan-86;136/8101;0.768641693;0.861457426;0.808130228;C1QA;1
VIP;hsa05418;Fluid shear stress and atherosclerosis;Jan-86;139/8101;0.776056081;0.861457426;0.808130228;CALM1;1
VIP;hsa04140;Autophagy - animal;Jan-86;141/8101;0.780868028;0.861457426;0.808130228;PRKACB;1
VIP;hsa04550;Signaling pathways regulating pluripotency of stem cells;Jan-86;143/8101;0.785577757;0.861457426;0.808130228;WNT5A;1
VIP;hsa05017;Spinocerebellar ataxia;Jan-86;143/8101;0.785577757;0.861457426;0.808130228;ATP2A1;1
VIP;hsa04072;Phospholipase D signaling pathway;Jan-86;148/8101;0.796918845;0.861615473;0.808278492;PDGFRA;1
VIP;hsa04723;Retrograde endocannabinoid signaling;Jan-86;148/8101;0.796918845;0.861615473;0.808278492;PRKACB;1
VIP;hsa05226;Gastric cancer;Jan-86;149/8101;0.799114869;0.861615473;0.808278492;WNT5A;1
VIP;hsa04218;Cellular senescence;Jan-86;156/8101;0.813843485;0.87262107;0.818602803;CALM1;1
VIP;hsa04217;Necroptosis;Jan-86;159/8101;0.819824138;0.87417712;0.820062529;FTL;1
VIP;hsa04630;JAK-STAT signaling pathway;Jan-86;162/8101;0.825614815;0.875514611;0.821317224;PDGFRA;1
VIP;hsa05225;Hepatocellular carcinoma;Jan-86;168/8101;0.836649913;0.879430468;0.824990676;WNT5A;1
VIP;hsa04530;Tight junction;Jan-86;169/8101;0.838420757;0.879430468;0.824990676;PRKACB;1
VIP;hsa05152;Tuberculosis;Jan-86;180/8101;0.856690787;0.893736875;0.838411467;CALM1;1
VIP;hsa04621;NOD-like receptor signaling pathway;Jan-86;184/8101;0.862815056;0.89528659;0.83986525;DEFA1;1
VIP;hsa05202;Transcriptional misregulation in cancer;Jan-86;192/8101;0.874297995;0.900341912;0.84460763;DEFA1;1
VIP;hsa05167;Kaposi sarcoma-associated herpesvirus infection;Jan-86;194/8101;0.877016992;0.900341912;0.84460763;CALM1;1
VIP;hsa04510;Focal adhesion;Jan-86;201/8101;0.886083601;0.902580205;0.846707365;PDGFRA;1
VIP;hsa05415;Diabetic cardiomyopathy;Jan-86;203/8101;0.888550461;0.902580205;0.846707365;ATP2A1;1
VIP;hsa04740;Olfactory transduction;Feb-86;441/8101;0.952507294;0.962481192;0.902900273;CALM1/PRKACB;2
VIP;hsa05016;Huntington disease;Jan-86;306/8101;0.964180766;0.969202541;0.909205547;TUBB8;1
VIP;hsa05168;Herpes simplex virus 1 infection;Feb-86;495/8101;0.971439892;0.971439892;0.911304398;SRSF3/SRSF6;2